
















Supervisor: Dr Katherine Smith 
Co-supervisor: Professor Sharon Prince 
 
 
Division of Immunology 
Department of Pathology 
 
 
Presented for MSc Med in Clinical Science and Immunology 
Faculty of Health Sciences 

































The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 





Dr Katherine Smith, thank you for always encouraging and supporting me. I am grateful for 
your endless patience and for regularly reminding me that Science does not have to be so 
serious. Someday I hope to be as inspirational to one of my students.  
Professor Sharon Prince, thank you for accepting me into your laboratory. From day one I 
have felt extremely welcome and appreciated. Your enthusiasm for your research has inspired 
me to find something that I feel as passionate about. I truly value the time and effort you put 
into helping me become better student, scientist and person. 
I would like to thank the Prince Lab and Dr Jade Peres for being so accommodating of me 
and creating an environment where Science is both fun and challenging. Most importantly, 
thank you Jenna Bleloch, Alexis Neumann and Brunette Katsandegwaza. I am 
tremendously grateful for the time you took out of your busy PhD schedules to help me. The 
past two years year would not have been the same without your friendship.  
To Associate Professor William Horsnell, Dr Matthew Darby, Dr Tarryn Willmer, Alisha 
Chetty and Dr Georgia Shäfer thank you for your contributions to this project and for the 
much-needed advice you have given me. 
Thank you to Professor Awen Gallimore, Dr Sarah Lauder, Michelle Somerville and 
Kathryn Smart for welcoming me to Cardiff University and for making me feel at home for the 
4 months that I was with you. 
Lastly, to my family, thank you for being my biggest supporters. Mom and Dad, you always 
taught me to never give up and I hope that I have made you proud. 
This work was generously supported by the Oppenheimer Memorial Trust, The National 
Research Foundation and The National-Research Foundation – Deutscher Akademischer 
Austausch Dienst Scholarship. Opinions expressed, and conclusions arrived at, are those of 











Jacobs B-A, Chetty A, Horsnell WGC, Schäfer G, Prince S, Smith KA. 2018. Hookworm 
exposure decreases human papillomavirus uptake and cervical cancer cell migration through 
systemic regulation of epithelial-mesenchymal transition marker expression. Scientific Reports 
8:11547. http://www.nature.com/articles/s41598-018-30058-9 
Conferences 
Presenter at the South African Society of Biochemistry and Molecular Biology (SASBMB) and 
the Federation of African Societies of Biochemistry and Molecular Biology 
(FASBMB) conference (8-11 July 2018), North West University. Talk title (9 July 2018): Cancer 
Cell Behaviour Following Parasite Exposure 
Presenter/Poster Presentation (TBA) at Molecular and Cellular Biology of Helminth Parasites 
VI conference (2-7 September 2018), Hydra, Greece. Talk title: Cancer Cell Behaviour 
Following Parasite Exposure 
Research Presentations 
Presenter at a Co-Infection Seminar: Helminth-Mediated Modulation of Bystander Immune 
Responses (7-8 March), University of Cape Town. Talk title (8 March): Cancer Cell Behaviour 
Following Parasite Exposure 
Poster presentation at the University of Cape Town Human Biology/Integrative Biomedical 
Sciences/Pathology Postgraduate Research Day (27 September) 
Presenter at a Cell Biology Seminar: Division of Cell Biology Lunchtime Research Seminars, 
University of Cape Town. Talk title (28 September 2017 and 27 February 2018): Cancer Cell 




This thesis/dissertation has been submitted to the Turnitin module and I confirm that my 
supervisor has seen my report and any concerns revealed by such have been resolved with 
my supervisor. 
Signature 
Date: 6 August 2018 
4 
 
Table of Contents 
Acknowledgements………………………………………………………………………............. 1 
Research Outputs……………………………………………………………………………..…... 2 
Plagiarism Declaration…………………………………………………………………………..... 3 
Table of Contents………………………………………………………………………………….. 4 
List of Abbreviations….…………………………………………………………………………... 7 
List of Figures….................................................................................................................. 10 
Abstract………………………………………………………………………………...................  13 
1. Introduction….…………………………………………………………………………............ 14 
 1.1 Cancer 
 1.2 Helminths 
 1.3 The Immune Response to Helminths 
 1.4 Systemic Immune Suppression Cause by Helminth Infection 
 1.5 Helminths and Cancer 
 1.6 Cervical Cancer and Helminths 
1.7 Colorectal Cancer and Helminths 
1.8 Helminth Therapy 
1.9 Helminths and Cancer Treatment 
1.10 Aims and Objectives 
2. Materials and Method...…………………………………………………….......................... 30 
 2.1 Helminth Antigen Preparation 
  2.1.1 Nippostrongylus brasiliensis L3 Antigen  
2.1.2 Heligmosomoides polygyrus Antigen and HES  
2.1.3 Verification of HES Immune-Regulatory Effects 
2.2 Limulus Amebocyte Lysate (LAL) Assay 
2.3 Cell Line Culture 
2.4 Mycoplasma Testing 
2.5 In vitro Assays 
 2.5.1 Growth Curve Assay 
 2.5.2 Scratch Motility Assay 
 2.5.3 Transwell Migration Assay 
5 
 
2.5.4 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
Assay 
2.5.5 Bromodeoxyuridine (BrdU) Incorporation Assay 
2.5.6 Western Blotting 
   2.5.6.1 Protein Extraction 
2.5.6.2 SDS-PAGE 
  2.5.6.3 Transfer 
  2.5.6.4 Detection 
2.5.7 Flow Cytometry on Cell-Surface Vimentin Staining  
2.5.8 HPV16 Pseudovirion Internalisation Assay 
2.6 In vivo Experiments 
2.6.1 Mice 
 2.6.2 Western Blotting on Murine Female Genital Tract (GFT) Tissue 
2.6.3 Colorectal Cancer Model 
2.6.4 The Effect of HES on Colitis-Associated Colorectal Cancer (CAC) 
Development in vivo 
2.6.5 The Effect of the TGF-β Mimic Contained in HES on CAC Development 
in vivo 
2.7 Statistical Analysis 
3. Results.………………………………………………………................................................. 56 
3.1 Investigating the Effect of Parasite Antigen on Cervical Cancer Behaviour in vitro  
3.1.1 Nippostrongylus brasiliensis L3 Antigen Does Not Affect HeLa 
Proliferation 
3.1.2 N. brasiliensis L3 Antigen Significantly Reduces HeLa Cell Migration and 
Expression of EMT Markers  
3.1.3 N. brasiliensis L3 Antigen Significantly Reduces Ca Ski Cell Migration 
3.1.4 N. brasiliensis L3 Antigen Significantly Reduces C33-A Cell Migration and 
Expression of EMT Markers 
3.1.5 N. brasiliensis Infection Reduces the Expression of EMT Makers in the 
Mouse Female Genital Tract (FGT) 
3.1.6 Cell-Surface Vimentin Expression and HPV16 Pseudovirion 
Internalisation is Diminished in N. brasiliensis L3 Antigen Treated HeLa Cells 
3.2 Investigating the Effect of Heligmosomoides polygyrus Derived Antigens on 
Colorectal Cancer Behaviour in vitro 
3.2.1 H. polygyrus Derived Antigens Significantly Decrease Colorectal Cancer 




3.2.2 H. polygyrus Derived Antigens Significantly Alter Colorectal Cancer Cell 
Migration 
3.2.3 HES Significantly Increases Mouse CT26.WT Colorectal Cancer Tumour 
Growth 
3.3 Investigating the Role of HES in a Murine Model of Colitis-Associated Colorectal 
Cancer (CAC) 
3.3.1 HES Treatment Worsens Pathology in a Murine Model of CAC 
3.3.2 Increased morbidity and mortality induced by HES treatment is TFG-β 
dependent 
4. Discussion...……………………………………………………............................................ 89 
4.1 The role of N. brasiliensis in cervical cancer development and progression 
4.2 The influence of H. polygyrus derived antigens on colorectal cancer in vitro 
4.3 H. polygyrus derived antigens and in vivo colorectal cancer tumour growth 
4.4 The involvement of HES and TGF-β in colitis-associated colorectal cancer (CAC) 
5. Conclusion……………………………………………………............................................... 97 
6. Future Work…………………………………………………................................................. 98 
7. References..……………………………………………………........................................... 102 
8. Appendix…...…………………………………………………............................................. 115 
8.1 Heligmosomoides polygyrus antigen and HES Preparation 
8.2 Cell Line Culture 
8.3 Mycoplasma Testing 
8.4 In vitro Assays 
 8.5 Western Blotting 





List of Abbreviations 
AAMΦ – Alternatively-activated macrophages 
AOM – Azoxymethane 
APC – Adenomatous polyposis coli 
Apc – allophycocyanin  
ATCC – American Type Culture Collection 
BrdU – Bromodeoxyuridine 
Brev A – Brefaldin A 
BV – Brilliant Violet 
BSA – Bovine Serum Albumin 
CAC – Colitis-Associated Colorectal Cancer 
CAMΦ – Classically-activated macrophages 
CCA – Cholangiocarcinoma 
CD – Crohn’s Disease 
CFSE - Carboxyfluorescein Succinimidyl Ester 
CHO – Chinese Hamster Ovary  
CRC – Colorectal Cancer 
DALY – Disability-Adjusted Life Years 
DAPI - 4',6-diamidino-2-phenylindole 
DC – Dendritic Cell 
dLN – Draining Lymph Node 
DSS – Dextran Sulphate Sodium 
DMEM – Dulbecco’s Modified Eagle Medium 
DNBS – Dinitrobenzene Sulfonic Acid  
EBV – Epstein Barr Virus 
ECL – Enhanced Chemiluminescence 
ECM – Extracellular Matrix 
EDTA – Ethylenediaminetetraacetic acid 
EMT – Epithelial-Mesenchymal Transition 
ES – Excretory-Secretory 
FBS – Foetal Bovine Serum 
FGS – Female Genital Schistosomiasis 
FGT – Female Genital Tract 
FITC – Fluorescein isothiocyanate  
Foxp3 – Forkhead box p3 
HBV – Hepatitis B Virus 
8 
 
HCV – Hepatitis C Virus  
HES – Heligmosomoides polygyrus excretory-secretory product 
HEV – High Endothelial Venule 
HIC – High-Income Countries 
HPV – Human Papillomavirus 
HTLV-1 – Human T-Cell Leukemia/Lymphoma Virus Type 1 (HTLV-1) 
IBD – Inflammatory Bowel Disease 
IL-4Rα – IL-4 Receptor Alpha 
ILC – Innate Lymphoid Cells 
ILC-2 – Group 2 Innate Lymphoid Cells 
IP injection – Intraperitoneal Injection 
LAL - Limulus Amoebocyte Lysate 
LMIC – Low- and middle-income countries 
LPS – Lipopolysaccharide 
MALT – Mucosal Associated Lymphoid Tissue 
MC – Mast cell 
MCPyV – Merkel Cell Polyomavirus (MCPyV) 
miRNA – microRNA  
MLN – Mesenteric Lymph Node 
MTT – Methylthiazol Tetrazolium 
ndLN – Non-Draining Lymph Node 
OD – Optical Density 
PBS and PBS/T – Phosphate Buffered Saline and Phosphate Buffered Saline/Tween 
pRB – Phosphorylated Retinoblastoma  
PE – Phycoerythrin  
PerCp – Peridinin Chlorophyll Protein  
PerCpCy5.5 – Peridinin Chlorophyll Protein Cyanine 5.5  
PeCy7 – Phycoerythrin Cyanine 7 
PMA – Phorbol Myristate Acetate 
Rpm – Revolutions per minute 
RPMI – Roswell Park Memorial Institute Medium 
RSV – Respiratory Syncytial Virus 
SCC – Squamous Cell Carcinoma 
SDS-PAGE – Sodium-Dodecyl-Sulphate Polyacrylamide Gel Electrophoresis  
SEA – Schistosoma mansoni Egg Antigen 
STH - Soil-Transmitted Helminths 
T1D – Type 1 Diabetes 
9 
 
T2D – Type 2 Diabetes 
TBS and TBS/T – Tris-Buffered Saline and Tris-Buffered Saline/Tween 
TcES – Taenia crassiceps excretory-secretory product 
TGF-β – Transforming Growth Factor β  
Th1 – Type-1 immune response 
Th2 – Type-2 immune response 
Th17 – Type-17 immune response 
TNBS – Trinitrobenzene Sulphonic Acid 
Tregs – Regulatory T cells  
TspES – Trichinella spiralis excretory-secretory product 
UC – Ulcerative Colitis 
UGS – Urogenital Schistosomiasis 



















List of Figures 
Introduction: 
Figure 1.1: The predicted cancer incidence in 2035 in A. LMIC compared to B. HIC, adapted 
from GLOBOCAN 2012 
Figure 1.2: The proportion of worldwide cancer cases caused by infectious diseases, adapted 
from American Cancer Society 2017 
Figure 1.3: Worldwide helminth prevalence, adapted from the World Health Organisation 
2009. 
Figure 1.4: The immune response induced by intestinal helminths 
Figure 1.5: Summary of the effect of helminth infection on vaccine efficacy, autoimmune 
diseases and allergy and viral and bacterial co-infection 
Figure 1.6: The predicted cervical cancer incidence in 2035 in A. LMIC compared to B. HIC, 
adapted from GLOBOCAN, 2012 
Figure 1.7: The predicted colorectal cancer incidence in 2035 in A. LMIC compared to B. HIC, 
adapted from GLOBOCAN 2012 
Figure 1.8:  The Th2 response elicited by intestinal helminth infection could be of therapeutic 
potential in patients with IBD by abrogating the characteristic Th1 profile 
Figure 1.9: Increased expression of mesenchymal markers and decreased expression of 
epithelial markers leads to Epithelial-Mesenchymal Transition and metastasis  
Materials and Methods: 
Figure 2.1: The lifecycle of N. brasiliensis 
Figure 2.2: The lifecycle of H. polygyrus 
Figure 2.3: H. polygyrus adult worm isolation 
Figure 2.4: Gating strategy applied to obtain the Foxp3+ T cell population 
Figure 2.5: HES induces Foxp3+ T cell population expansion and reduces CD4+ T cell 
proliferation 
Figure 2.6: Two-Dimensional scratch-motility assay 
Figure 2.7: Transwell migration assay 
Figure 2.8: MTT reaction 
Figure 2.9: BrdU Incorporation Assay 
Figure 2.10: Western blot transfer set-up 
Figure 2.11: Protein detection by enhanced chemiluminescence 
Figure 2.12: Gating strategy applied to cells, analysed by flow cytometry, to obtain the cell-
surface vimentin positive population 
Figure 2.13: Gating strategy applied to cells, analysed by flow cytometry, to obtain the HPV16 
pseudovirion positive population 
11 
 
Figure 2.14: Experimental setup followed to determine the effect of N. brasiliensis infection on 
EMT marker expression in the mouse FGT 
Figure 2.15: Gating strategy applied to cells of the draining (dLN) and non-draining (ndLN) 
lymph nodes 
Figure 2.16: Gating strategy applied to CT26.WT tumour cells 
Figure 2.17: Experimental setup followed to determine the effect of HES on the development 
of colitis-associated colorectal cancer (CAC) 
Figure 2.18: Gating strategy applied to splenocytes 
Figure 2.19: Experimental setup followed to determine the effect of the TGF-β mimic in HES 
on the development of colitis-associated colorectal cancer (CAC) 
Figure 2.20: SB-431542 method of action 
Figure 2.21: Criteria used to calculate the total distress score for each mouse 
Figure 2.22: Gating strategy applied to splenocytes 
Results: 
Figure 3.1: N. brasiliensis L3 antigen does not affect HeLa cell proliferation 
Figure 3.2: N. brasiliensis L3 antigen decreases HeLa cell migration  
Figure 3.3: N. brasiliensis L3 antigen decreases levels of EMT marker expression in HeLa 
cells 
Figure 3.4: N. brasiliensis L3 antigen decreases Ca Ski cell migration  
Figure 3.5: N. brasiliensis L3 antigen decreases C33-A cell migration  
Figure 3.6: N. brasiliensis L3 antigen decreases levels of EMT marker expression in C33-A 
cells 
Figure 3.7: N. brasiliensis infection leads to reduced EMT marker expression in mouse female 
genital tracts (FGTs) 
Figure 3.8: N. brasiliensis L3 antigen decreases HeLa cell-surface vimentin expression 
Figure 3.9: N. brasiliensis L3 antigen decreases HPV16 pseudovirion internalisation by HeLa 
cells 
Figure 3.10: H. polygyrus derived antigens decrease CT26.WT cell proliferation and increase 
cell cycle regulator protein expression 
Figure 3.11: HES, but not H. polygyrus antigen, decreases CT26.WT cell viability and BrdU 
incorporation 
Figure 3.12: H. polygyrus derived antigens decrease HCT116 cell proliferation and increase 
cell cycle regulator protein expression 
Figure 3.13: H. polygyrus antigens alter colorectal cancer cell migration in a species-specific 
manner 
Figure 3.14: HES significantly accelerates CT26.WT tumour growth 
12 
 
Figure 3.15: HES elevates total CD4+ and CD8+ T cell numbers in the draining lymph node 
(dLN) of mice bearing tumours derived from HES treated CT26.WT cells  
Figure 3.16: HES significantly increases the proportion and number of regulatory Foxp3+ T 
cells in the draining lymph node (dLN) of tumours derived from treated CT26.WT cells 
Figure 3.17: HES significantly increases the number of regulatory Foxp3+ T cells in CT26.WT 
tumours 
Figure 3.18: HES significantly decreases the proportion of CD11b+ cells in CT26.WT tumours 
Figure 3.19: H. polygyrus derived antigens significantly increase the number neutrophils in 
CT26.WT tumours  
Figure 3.20: HES worsens pathology in a murine model of colitis-associated colorectal cancer 
(CAC) 
Figure 3.21: HES worsens pathology in a murine model of CAC 
Figure 3.22 HES treatment increases the CD11b+, eosinophil and neutrophil populations in a 
murine model of CAC 
Figure 3.23: HES treatment decreases the total CD4+ and CD4- populations in a murine model 
of CAC 
Figure 3.24: Increased morbidity and mortality induced by HES treatment is TFG-β dependent 
Figure 3.25: Increased CD11b+ proportions and total cell counts, induced by HES treatment, 
is TFG-β dependent 
Figure 3.26: The effect of HES treatment on the CD4+ and CD4- population is TFG-β 
independent 
Discussion: 
Figure 4.1: Summary of results  














Infectious diseases, including helminthiases, are estimated to cause 16.1% of global cancer 
cases. While certain helminths are conclusive causes of cancer, others have been shown to 
reduce the disease. It is currently unknown why differing helminth infections promote or 
prevent cancer development and progression, or which cellular mechanisms are altered 
following exposure. Using several in vitro and in vivo techniques, this study aimed to determine 
the effect that certain helminths have on the progression of cervical and colorectal cancer. 
The results revealed that antigen from the hookworm Nippostrongylus brasiliensis significantly 
reduced cervical cancer cell migration and the expression of two markers of metastasis: 
vimentin and N-cadherin. Importantly, N. brasiliensis antigen significantly lowered the 
expression of cell-surface vimentin, while decreasing Human Papillomavirus type16 
pseudovirion internalization. In vivo infection with N. brasiliensis significantly decreased 
vimentin expression within the female genital tract, confirming the relevance of these in vitro 
findings. Furthermore, exposure to antigen from the gastrointestinal nematode 
Heligmosomoides polygyrus decreased the in vitro proliferation of human and mouse 
colorectal cancer cells and simultaneously increased the expression of cell cycle regulator 
proteins, p53 and p21. Surprisingly, while antigen from H. polygyrus inhibited human colorectal 
cancer cell migration, it had the opposite effect on mouse colorectal cancer cells, suggesting 
that its impact on colorectal cancer migration may be, at the very least, species dependent. 
Using a syngeneic tumour model, the excretory-secretory product from H. polygyrus was 
shown to significantly increase tumour growth and the expansion of regulatory T cells and 
neutrophils in the tumour. Similarly, in a model of colitis-associated colorectal cancer this 
antigen significantly worsened pathology in a TGF-β dependent manner. Undoubtedly, the 
knowledge gained from this study will contribute to the limited understanding about helminths 






Cancer is a disease characterised by uncontrolled cell proliferation which has the potential to 
spread throughout the body (National Health Service, 2016). Importantly, over recent years, 
inflammation has been shown to play a critical role in tumour progression (1). Cancer causes 
significant worldwide morbidity and mortality with an estimated 14.1 million new cases and 8.2 
million deaths occurring in 2012 alone (2). Notably, the cancer burden is more prominent in 
low- and middle-income countries (LMIC) where it accounts for 57% of cases and 65% of 
deaths. It is estimated that over the next two decades the incidence of cancer will increase by 













It has been predicted that four in ten cancer cases could be prevented by reducing specific 
risk factors. These include smoking, exposure to ultraviolet (UV) radiation, an unbalanced diet 
and overeating, minimal physical exercise, excessive alcohol consumption and contact with 
certain infectious diseases (Cancer Research UK). 
In developing regions significantly more cancer cases are attributable to chronic infectious 
diseases. Astoundingly, more than a third of new cancer cases in sub-Saharan Africa are 
attributable to chronic infectious disease (Figure 1.2) (3, 4). Epstein Barr Virus (EBV), 
Hepatitis B and C Viruses (HBV and HCV), Kaposi Sarcoma-Associated Herpesvirus, Human 
Figure 1.1: The predicted cancer incidence in 2035 in A. LMIC compared to B. HIC, adapted from 
GLOBOCAN 2012. Yellow areas indicate the worldwide cancer incidence in 2012 and blue areas 
indicate the predicted increase in cancer incidence between 2012 and 2035. The x-axis represents the 








Papillomavirus (HPV), Merkel Cell Polyomavirus (MCPyV) and Human T-Cell 
Leukaemia/Lymphoma Virus Type 1 (HTLV-1) are all strongly associated with an increased 
risk of cancer development. Furthermore, the bacterium Helicobacter pylori, which the Centre 
for Disease Control estimates to be present within two-thirds of the population, can cause 











Figure 1.2: The proportion of worldwide cancer cases caused by infectious diseases, adapted from 
American Cancer Society 2017 (4). 
 
While less thoroughly understood, some helminth infections have also been linked to an 
elevated risk of developing certain cancers. For example, S. haematobium, Opisthorchis 
viverrini and Clonorchis sinensis are all classified as group one biological carcinogens and are 
conclusive causes of cancer (5-7). 
1.2 Helminths 
Helminths are one of the most common infectious agents in LMIC, infecting over a billion 
people in sub-Saharan Africa, Asia and the Americas (Figure 1.3) (8, 9). These large, 
multicellular parasitic worms have a considerable disease burden resulting in the loss of 14 
million disability-adjusted life years (DALY - the amount of years lost due to illnesses, disability 
or premature death) (8). The gastrointestinal tract of an individual living in a developing country 
is likely to be parasitised by one if not all three of the leading soil-transmitted helminths (STH): 
roundworms (Ascaris lumbricoides), hookworms (Necator americanus or Ancylostoma 
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duodenale) and whipworms (Trichuris trichiura) (10). Globally, 807 million people are infected 
with roundworms, 700 million are infected with hookworms and 604 million are infected with 
whipworms (The End Fund, 2016). Furthermore, each year an estimated 240 million people 
are infected with the vascular trematode Schistosoma. Schistosomiasis ranks second to 
malaria as the most prevalent parasitic disease (Global Network – Neglected Tropical 












1.3 The Immune Response to Helminths 
As seen in Figure 1.4, helminth infections are typically characterised by a type-2 (Th2) 
immune response (11). This response centres around the production of specific cytokines (IL-
4, IL-5, IL-9, IL-10 and IL-13), which limit type-1 (Th1) immune responses while amplifying 
Th2 immunity (12). In addition, the action of B cells and cells of the innate immune system, 
including dendritic cells (DCs), eosinophils, mast cells (MCs), type 2 innate-lymphoid cells 
(ILC-2s) and basophils all contribute to efficiently expelling the parasite (13).  
The differentiation of Th2 cells depends on the activation of transcription factors STAT6 and 
STAT5 by cytokines IL-4 and IL-2 respectively. Activation of STAT6 results in the expression 
of GATA3, which together with STAT5 causes the expression of Th2 specific genes. Following 
infection with the murine gastrointestinal nematode Heligmosomoides polygyrus, transgenic 
mice overexpressing GATA3 produced significantly higher amounts of IL-5 and IL-13 




highlighting the critical role of GATA3 in controlling the production of Th2 cytokines (14). 
Importantly, helminths, including H. polygyrus, are understood to promote the development of 
an anti-inflammatory immune tolerant environment in order to facilitate their survival in the 
host (15). This involves the amplification of regulatory cell populations including regulatory T 
cells (Tregs), regulatory B cells and alternatively activated macrophages (AAMΦ). Moreover, 
helminth infections favour the production of anti-inflammatory cytokines (IL-4, IL-10 and 






















Tregs play a crucial role in immune suppression and limiting the development of autoimmune 
diseases (18, 19). This cell population is made up of natural Tregs, which are produced in the 




thymus, and inducible Tregs, which are derived from circulating conventional T cells in the 
presence of IL-10, TGF-β and retinoic acid (20-22). Notably, both subsets constitutively 
express the transcription factor Forkhead Box P3 (Foxp3) (23). Certain helminths, including 
H. polygyrus, Brugia malayi, Echinococcus granulosus, Schistosoma mansoni and Trichinella 
spiralis, expand the Foxp3+ T cell population thereby contributing to immune suppression, 
limiting damage to the host and favouring survival of the parasite (16, 24-27). Unsurprisingly, 
several studies have shown that due to an enhanced Th2 response, Treg depletion in the host 
promotes parasite expulsion (28-30). The excretory-secretory (ES) products secreted by 
helminths similarly contributes towards suppression of the host immune response (27, 31, 32). 
Of particular relevance to the current study is H. polygyrus ES (HES), which contains an 
equivalent of the mammalian TGF-β and induces de novo Foxp3+ T cell population expansion 
in mice and humans (16, 33).   
In addition to Tregs, helminths promote the AAMΦ populations. In response to pro-
inflammatory cytokines such as IFN-Ɣ, bone-marrow derived macrophages differentiate into 
classically activated macrophages (CAMΦs) and in contrast, anti-inflammatory cytokines 
cause bone-marrow derived macrophages to differentiate into AAMΦs (34). In response to 
intestinal helminth infection, IL-4 and IL-13 stimulate the production of AAMΦs which function 
to dampen the inflammatory response to the parasite, repair tissue damage and, through their 
production of retinoic acid, induce the differentiation of Tregs (35, 36). However, AAMΦs can 
also play a role in parasite expulsion in part by causing morphological and functional changes 
to the smooth muscle of the host intestinal lumen and by limiting larvae motility, thus further 
reducing host tissue damage (37-40). 
ILCs are a critical component of innate immunity, regulating inflammation and tissue 
homeostasis (41). ILCs depend on IL-7 for their development and maintenance and can be 
further divided into three subsets depending on effector functions, cytokine expression and 
transcriptional profile (42). Fully matured Group 2 ILCs (ILC-2s) play a crucial role in initiating 
and amplifying in vivo Th2 responses which are important for helminth expulsion (43). 
Following helminth-induced tissue damage, ILC-2s are activated by epithelial cytokine 
alarmins IL-25, thymic stromal lymphopoietin (TSLP) and IL-33 and release IL-5, IL-9, IL-13 
and a small amount of IL-4 (44, 45). Furthermore, IL-25 release by intestinal tuft cells (a 
chemosensory cell population located in the intestinal epithelium) induces IL-13 production by 
ILC-2s, which expands the tuft cell population, and further promotes the development of a Th2 
response and parasite expulsion (46, 47). Naturally, ILC-2 activation is targeted as a 
mechanism for immune evasion by helminths. MHCII-expressing ILC-2s interact with antigen-
specific T cells and thereby initiate and amplify IL-13 production (48). For this reason, 
depletion of MHCII on ILC-2s in N. brasiliensis infected mice decreased the potential for 
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helminth elimination and was associated with decreased IL-13 levels. Similarly, H. polygyrus 
promotes the release of host-derived IL-1β, causing decreased IL-33 and IL-25 production, 
and ultimately reduced ILC-2 activation and impaired helminth elimination (49). H. polygyrus 
derived HES has also been shown to decrease IL-33 production and ILC-2-derived Th2 
cytokine release in order to prevent the development of a Th2 response (50). 
In addition to the responses mentioned above, helminth infections have multiple other effects 
on the cells of the host immune system. Antigen-presenting cells, including DCs, have likewise 
been implicated in contributing towards the Th2 response to helminthiases (51). CD11c (hi) 
and CD11c (lo) DCs induce antigen-specific CD4+ T cell activation and Treg production 
respectively (52, 53). Furthermore, helminth-activated DCs produce IL-10 and in doing so, 
further stimulate the development of Tregs (54). Basophils are similarly central to the effector 
phase of the Th2 immune response by releasing IL-4, IL-5 and IL-13 which promote AAMΦ 
differentiation and eosinophilia (55). MCs play a role in orchestrating a Th2 immune response 
via the regulation of tissue-derived cytokines and prostaglandin E2 contributes to a Th2 
immune response by inhibiting pro-inflammatory cell attraction and the production of Th1 
cytokines (56, 57). 
1.4 Systemic Immune Suppression Caused by Helminth Infection 
In addition to the local response induced by helminths, these parasites can also have systemic 
effects on the immune system. There is epidemiological evidence to suggest that helminth 
infections can dampen the efficacy of vaccination. In sub-Saharan Africa, vaccinated infants 
born to woman who had lymphatic filariasis, schistosomiasis, or hookworm infection during 
pregnancy had an impaired ability to develop an IgG response to Haemophilus influenza, 
diphtheria, hepatitis B and tetanus toxoid antigen (58). Moreover, tetanus toxoid-specific 
antibody titres and IFN-Ɣ levels were found to be lower in vaccinated individuals previously 
infected with the nematode Onchocerca volvulus (59).  
These parasitic worms are also able to alter the immune response to co-infection with viruses. 
An epidemiological study in Uganda revealed that 35% of HIV-positive participants were 
infected with the hookworm N. americanus and consequently, had further reduced CD4+ T 
cell counts (60). Furthermore, mice co-infected with Vaccinia virus and the roundworm A. 
lumbricoides had an increased mortality rate and elevated lung viral titres compared to virus-
only infected mice (61). This correlated with a reduced virus-specific immune response 
involving CD8+ T cells and IFN-Ɣ producing CD4+ T cells. In contrast, H. polygyrus infection 
lessened lung inflammation and viral load in mice co-infected with Respiratory Syncytial Virus 
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(RSV) in a Th2 independent manner involving type 1 interferon signalling and the microbiome 
(62). 
Helminth infection likewise alters the immune response to bacterial co-infection. Individuals 
with latent tuberculosis who were co-infected with the roundworm Strongyloides stercoralis 
had reduced levels of all B cell subsets, and subsequently lowered IgG and IgM, which was 
reversed following anthelmintic treatment (63). H. polygyrus and Citrobacter rodentium co-
infected mice had increased morbidity and mortality accompanied by C. rodentium-associated 
intestinal injury, elevated TNF-α and reduced IFN-Ɣ levels. Significantly, co-infected STAT6 
knockout mice did not establish a robust C. rodentium infection highlighting the Th2 
mechanism that helminths employ to influence host susceptibility to bacterial infections (64). 
In the same way, mice infected with H. polygyrus and S. typhimurium establish advanced 
colonic inflammation, compared to S. typhimurium only infected mice, and have increased 
morbidity relating to elevated IL-10 and lowered neutrophil recruitment (65). H. polygyrus 
infection has also been shown to alter the intestinal metabolome leading to an enhanced 
susceptibility to S. typhimurium co-infection (66).  
Of significant interest is that helminth infections can benefit the host, limiting autoimmune and 
allergic symptoms in infected hosts. Short-term infection with H. polygyrus prevented the onset 
of disease in a murine model of type 1 diabetes (T1D), which was associated with reduced 
STAT6 expression, decreased Foxp3+ T cell population expansion and elevated IL-10 
levels (67). Blocking IL-10 signalling in non-obese diabetic (NOD) IL-4 knockout mice (IL-
4−/−) reversed this effect and caused pancreatic β-cell destruction and the onset of T1D. 
However, CD4+ T cell transfer from infected mice to NOD IL-4−/− mice did not result in the 
development of T1D, highlighting the possibility that H. polygyrus protects against T1D in 
an IL-10 dependent but Th2 independent manner. The Th2 immune response elicited by 
infection with H. polygyrus has also been shown to contribute towards the control of type 2 
diabetes (T2D) (68). Using a murine model of T2D (KK-Ay/TaJcl mice), H. polygyrus infection 
resulted in improved blood glucose levels and decreased the levels of markers associated 
with T2D in the liver. This seemingly protective effect of helminth exposure on the risk of 
developing diabetes was also observed in a large cohort in southern India. This study revealed 
that 2.6% of glucose tolerant individuals had a lymphatic filariasis infection compared to 0% 
in individuals with T1D (69). Additionally, filarial-specific antibodies were present in 28% of 
healthy participants compared to only 2% in T1D individuals. 
Treatment with Trichuris suis ES before onset of autoimmune encephalomyelitis, a murine 
model of multiple sclerosis, decreased the inflammatory Th1 and type-17 (Th17) immune 
responses in the spinal cord and spleen and ultimately lowered disease severity (70). In two 
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independent models of arthritis, N. brasiliensis and H. polygyrus infection prevented bone loss 
and arthritis severity associated with an elevated Th2 response and diminished levels of pro-
inflammatory cytokines in the joints (71, 72). In a murine model of atopic asthma, H. polygyrus 
infection suppressed allergen-induced bronchial hyper-reactivity associated with lowered 
airway eosinophilia and increased IL-10 dependent Treg production (73). A similar result can 
be observed when sensitized mice are treated with HES, however this effect was associated 
with lowered ILC-2 activation (74, 75). Furthermore, in a murine model of allergic airway 
inflammation, compared with sensitized and airway challenged controls H. polygyrus infected 
mice had reduced eosinophil and lymphocyte recruitment into the lungs and decreased 











The immune-regulatory properties demonstrated following helminth infection could suggest a 
favourable outcome when used in the treatment of chronic inflammatory diseases. Cancer is 
an inflammatory condition accompanied by an immune response mediated mostly by INF-Ɣ 
(77-79). As previously described, the Th2 response induced by helminth infections does not 
favour INF-Ɣ production and it is, therefore possible that helminths could exacerbate cancer 
progression by limiting the anti-tumour immune response (11).  
1.5 Helminths and Cancer 
While the direct impact of helminths on cancer development and progression is unknown, 
these parasites have been shown to influence susceptibility to cancer-causing viruses and 
bacteria. A recent study showed that persistent STH infection, with S. stercoralis, hookworm, 
Figure 1.5: Summary of the effect of helminth infection on vaccine efficacy, autoimmune 
diseases and allergy and viral and bacterial co-infection. Beneficial outcomes are depicted with 
green arrows, detrimental outcomes with red arrows and both beneficial and detrimental outcomes 




A. lumbricoides, and/or Trichuris trichurid, alters the immune response to favour HPV infection 
and as a result significantly increases HPV prevalence and consequently the risk of cervical 
cancer development (80). Furthermore, STHs are able to activate the oncogenic Kaposi’s 
sarcoma herpesvirus from latency greatly increasing the risk of developing Kaposi’s sarcoma 
in the future (81).  
The carcinogenic trematode O. viverrini greatly increases the risk of cholangiocarcinoma 
(CCA) development. However, when co-infected with the bacterium H. pylori, which is strongly 
associated with an increased risk of gastric cancer, increased H. pylori growth, liver fibrosis 
and expression of pro-inflammatory cytokines was observed (82, 83). In contrast, S. mansoni 
and several other STHs have been shown to reduce the risk of H. pylori-induced gastric cancer 
by dampening the Th1 response initiated by the cancer-causing bacterium  (84-90).  
Currently, a consensus on how STH infections impact cancer development and progression 
has not been reached. 
1.6 Cervical Cancer and Helminths  
Globally, cervical cancer is the fourth most common cancer in woman, causing an estimated 
266 000 deaths in 2012. Significantly, 87% of cervical cancer-related deaths occur in LMIC 
and it is estimated that by 2035, the incidence will increase by 58% (from 444 546 to 702 152 










Nearly 100% of new cervical cancer cases are attributable to chronic infection with HPV (4). 
Although recent epidemiological evidence suggests that persistent STH infection alters the 
immune response to HPV, exactly how STHs and other helminths influence cancer is only fully 
Figure 1.6: The predicted cervical cancer incidence in 2035 in A. LMIC compared to B. HIC, adapted 
from GLOBOCAN 2012. Yellow areas indicate the worldwide cervical cancer incidence in 2012 and 
blue areas indicate the predicted increase in cancer incidence between 2012 and 2035. The x-axis 








understood in a few contexts. For instance, S. haematobium is a conclusive cause of bladder 
cancer and the mechanism is thought to involve unresolved chronic inflammation which leads 
to genomic instability and tumour formation (7, 92). Indeed, chronic inflammation of the urinary 
bladder results from the deposition of S. haematobium ova in the tissue which causes Female 
Genital Schistosomiasis (FGS), a tissue reaction resulting in lesions which increase the risk 
of bleeding and discharge (93). This appears to be associated with an increased risk of cancer 
at this site, causing urogenital schistosomiasis (UGS)-induced carcinogenesis. Infection with 
S. haematobium, is further associated with cervical dysplasia and invasive squamous cell 
carcinoma (SCC), both of which predispose a female to cervical cancer (94). Moreover, it has 
been shown that populations with Schistosome infection have a significantly increased risk of 
infection with HPV types which are associated with an elevated risk of cervical cancer 
development (95). 
1.7 Colorectal Cancer and Helminths  
Globally, colorectal cancer (CRC) is the second and third most commonly diagnosed cancer 
in females and males respectively and is expected to have nearly doubled in incidence by 












Of significance, and in contrast to that of cervical cancer, is the fact that 60% of worldwide 
CRC cases occur in developed regions, with the highest mortality rates occurring in Central 
Figure 1.7: The predicted colorectal cancer incidence in 2035 in A. LMIC compared to B. HIC, adapted 
from GLOBOCAN 2012. Yellow areas indicate the worldwide colorectal cancer incidence in 2012 and 
blue areas indicate the predicted increase in cancer incidence between 2012 and 2035. The x-axis 










Europe and the lowest in Western Africa (91). It has been suggested that the lifestyle common 
in more developed countries, including a diet low in fibre, fruits and vegetables, obesity, lack 
of physical activity, excessive alcohol consumption and a lack of sleep increases the risk of 
developing CRC (97, 98). 
Chronic inflammation associated with Inflammatory Bowel Disease (IDB) has been linked to 
an increased risk of high-grade dysplasia and cancer known as colitis-associated colorectal 
cancer (CAC) (99). Although many STH establish life-long infections associated with chronic 
inflammation within the gastrointestinal tract, it is unclear how these infections directly impact 
CAC. In mouse models of CAC, infection with the tapeworm Taenia crassiceps and treatment 
with its ES products (TcES) inhibited colonic inflammatory responses and tumour formation 
(100, 101). More specifically, infection with T. crassiceps prevented the loss of intestinal goblet 
cells, promoted the negative immunomodulation of pro-inflammatory cytokines and prevented 
an increase in markers associated with CAC-tumorigenesis, β-catenin and CXCR2 (100). 
TcES-treated mice exhibited a similar result where the expression of pro-inflammatory 
cytokines, IL-1β, TNF-α and IL-17, were reduced compared to that in untreated mice (101). 
The generation of an anti-inflammatory environment was further promoted by the decreased 
expression of tumorigenesis markers COX2, β-catenin and STAT3 in the colon tissue. 
While the aforementioned studies suggest a favourable effect of helminth exposure on CAC, 
chronic and acute infection with the murine gastrointestinal nematode, Trichuris muris, 
enhanced tumour development in a model of spontaneous CRC (APCmin/+ mice) (102). 
Moreover, in a model of CAC, infection with H. polygyrus exacerbated tumour development 
and intestinal inflammation characterised by elevated IL-6 and CXCL1 levels (103). Further 
support of a detrimental role for helminths in CRC development was seen in a cohort of S. 
mansoni infected CRC patients who exhibited early onset of advanced multicentric CRC (104). 
As a result of the uncertain role that helminths play in IBD, several recent studies have 
emerged which investigate their use in the treatment of these inflammation-associated 
diseases. 
1.8 Helminth Therapy 
The immune-regulatory tactics employed by helminths to successfully evade expulsion from 
the host can contribute to the outcome of inflammatory illnesses, including IBD (105-107). 




While the exact cause of IBD, namely Crohn’s Disease (CD) and Ulcerative Colitis (UC), 
remains to be determined, it is presumed to be caused by the dysregulation of the intestinal 
mucosal immune system and microbiota (12, 108). Individuals with IBD suffer from chronic 
intestinal inflammation characterised by periods of remission and relapse. As depicted in 
Figure 1.8, CD can affect any part of the gut from the mouth to the rectum causing transmural 
inflammation, ulceration, granulomas, strictures and fistulae (12). Lymphocytes isolated from 
the inflamed intestines of individuals with CD secrete a pro-inflammatory Th1 pattern of 
cytokines including IFN-Ɣ and TNF-α (12). In contrast, UC only affects the large intestine with 
inflammation being the primary cause of discomfort (109). Furthermore, the immune response 
to UC is characterised by both Th1 (IFN-Ɣ and TNF-α) and Th2 (IL-13 and IL-5) typical 
cytokines (109). Interestingly, IL-17 levels are elevated in both active CD and UC patients 
(109). Indeed, the Th2 response elicited by intestinal helminth infection may help to abrogate 
Th1-induced inflammation by reducing Th1 cytokine production and could, therefore be of 
therapeutic potential in patients with IBD. 
To date, data obtained from clinical trials utilising helminths to treat IBD have been 
contentious. Human studies revealed that prolonged colonization with the human whipworm 
T. suis, as well as treatment with its ova, reduced disease severity in CD and UC patients 
(110, 111). Moreover, a case-control study in South Africa, dependent on self-reporting, 
demonstrated evidence for a potential protective effect of childhood helminth infection on the 
development of IBD later in life (112). However, other studies, which exhibited favourable 
results early on, ultimately did not show any beneficial effect on IBD patients and were either 










Figure 1.8:  The Th2 response elicited by intestinal helminth infection could be of therapeutic potential 




In vivo murine models of IBD (113) have been able to provide more reliable and reproducible 
results pertaining to the effect that helminths may have on IBD. Treatment with antigen derived 
from the nematode T. spiralis and infection with the rat tapeworm Hymenolepis diminuta 
caused a reduction in the severity of Dinitrobenzene Sulfonic Acid (DNBS)-induced colitis. 
This effect was associated with increased immune-regulatory cytokines, TGF-β, IL-13 and IL-
10 and decreased pro-inflammatory molecules iNOS and IL-1β (114-116). In contrast, other 
studies have shown that infection with H. diminuta worsened oxazolone-induced colitis by 
causing eosinophilia and increasing levels of disease-associated Th2 cytokines (117, 118). 
Although the role of T. crassiceps in CAC has been defined, pre-infecting mice with this 
tapeworm followed by the exposure to the inflammatory agent dextran sulphate sodium (DSS) 
significantly decreased signs and symptoms of DSS-induced colitis, weight loss and colon 
shortening (100, 101, 107). These results were accompanied by reduced pro-inflammatory 
cytokines (IL-17E and TNF-α) and elevated Th2 immune-regulatory cytokines (IL-4 and IL-
10). Interestingly, this beneficial role of helminth exposure on murine models of IBD does not 
necessarily depend on live infection. Pre-treating mice with S. japonicum ova lowered the 
mortality rate and pathology in Trinitrobenzene Sulfonic acid (TNBS)-induced colitis (119). 
This was found to result from increased expression of colonic epithelial tight junction proteins, 
ZO-1 and Occludin, reduced bacterial translocation, and ultimately lowered systemic 
inflammation. 
There is evidence to suggest that the cure of murine colitis depends on Treg accumulation in 
the intestinal lamina propria (120, 121). Owing to the immunosuppressive effects of Tregs, 
helminth therapy may prove beneficial in treating IBD due the increase in the Treg population 
following infection (16). Exposure to adult S. mansoni and S. mansoni ova beneficially 
modulated the host immune response to DSS- and TNBS-induced colitis respectively (26, 
122). Adult S. mansoni protection was associated with Treg population expansion and S. 
mansoni ova treatment decreased pro-inflammatory cytokines (IFN-Ɣ, IL-12 and IL-17) and 
increased immune-regulatory cytokines (IL-10 and TGF-β), leading to elevated Treg numbers 
(26, 122, 123). Additionally, infection with H. polygyrus inhibited colitis in an IBD susceptible 
mouse model (IL10-/- mice) by reducing pro-inflammatory Th1 cytokine release (IL-12 and IFN-
Ɣ) and promoting the formation of an anti-inflammatory environment rich in IL-13 and Tregs 
(124). This beneficial outcome has been further delineated to be caused by the expansion of 
tolerogenic DCs in infected mice, which block a pro-inflammatory immune response and 
promote an immune-regulatory one characterised by IL-10 and Tregs (125-127). In vast 
contrast to this, a more recent study found that H. polygyrus infection considerably 
exacerbated DSS-induced colitis by increasing the expression of inflammation-associated 
molecules IL-6 and CXCL1 (103). H. polygyrus has also been implicated in worsening S. 
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typhimurium enterocolitis as a result of lowered neutrophil recruitment to the intestines and 
elevated Th2 cytokine expression (65).  
While certain studies suggest a beneficial role for Tregs in the cure of murine colitis, studies 
in human CRC patients show that Tregs may disrupt the tumour-associated antigen-specific 
immune response. This has been demonstrated by the ability of Tregs, abundant in both the 
blood and lymph nodes of CRC patients, to suppress CD4+ T cell responses to tumour-
associated antigens leading to tumour recurrence (128, 129). Furthermore, Treg depletion 
from the peripheral blood mononuclear cells of the CRC patients unveiled the CD4+ T cell 
responses to the tumour-associated antigens (measured by IFN-Ɣ release) (129). This would 
implicate Tregs as a key driver of CRC disease instead of having therapeutic benefits. 
It is thought that IBD is contributed to by a dysregulated intestinal microbiota (108). An 
imbalance in the relationship between the macrobiota (including helminths), microbiota and 
the host promotes inflammatory responses and predisposes the host to a range of 
inflammatory and autoimmune diseases (130-132). T. muris infection in CD susceptible mice 
(NOD2-/-) prevented intestinal colonization by pro-inflammatory Bacteroides species resulting 
in an environment rich in protective Clostridia species (133). However, in a model of 
Citrobacter rodentium-induced colitis, H. polygyrus infection significantly altered the 
microbiome composition of mice by increasing detrimental Bacteroides species and 
decreasing beneficial Firmicutes and Lactobacillales (134). Importantly, mice who received 
gut microbiota from infected mice had worsened colitis symptoms and increased faecal 
pathogen shedding associated with increased Tregs and IL-10 levels. Notably, when Tregs 
were depleted and IL-10 neutralized, the enteropathogen-induced colitis symptoms were 
alleviated. Interestingly, an abundance in the rodent commensal L. taiwanensis has been 
shown to correlate with H. polygyrus infection as well as elevated Treg levels and the presence 
of a strong Th17 response (135). Moreover, administration of L. taiwanensis to H. polygyrus 
infected mice resulted in an increase in Treg levels leading to reduced helminth expulsion.   
1.9 Helminths and Cancer Treatment 
Tumour cells are able to acquire characteristics which allow them to invade the surrounding 
tissue and to metastasise to distal sites. Metastasis is associated with a poor outcome and is 
the major cause of mortality in patients with cancer. Invasion and metastasis is achieved by 
changes in cell shape and the deregulated expression of extracellular matrix (ECM) 
attachment proteins (136).  These changes promote cell migration, due to an increased level 
of motility, and often involve reduced expression of the invasion antagonist, E-cadherin, and 
increased expression of the invasion agonists, N-cadherin and vimentin. While E-cadherin is 
an adhesion molecule expressed by epithelial cells, N-cadherin and vimentin are adhesion 
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and type III intermediate filament proteins respectively expressed by mesenchymal cells. The 
switch in the expression of these invasion proteins is referred to as Epithelial-Mesenchymal 
Transition (EMT) and while essential in development and wound healing, it also plays a vital 
role in cancer by promoting the progression of a primary tumour towards a more invasive and 








Besides those which are conclusive causes of cancer, the direct impact that helminths have 
on invasion and metastasis is largely unclear and only a few studies have started to reveal 
possible associations (5-7). Compared to untreated tumours, antigen derived from S. 
haematobium accelerated the proliferation of Chinese Hamster Ovary (CHO) tumours with a 
corresponding increase in the levels of vimentin, suggesting that exposure to parasite derived 
antigens could drive EMT (138). Furthermore, when co-administered with a chemical 
carcinogen into the murine bladder wall, treatment with S. haematobium eggs reduced E-
cadherin expression, elevated vimentin expression and increased the proliferation of urothelial 
cells (139). Although not used in a cancer model, infection with H. polygyrus or T. spiralis 
increased epithelial permeability in the colon due to the decreased expression of E-cadherin 
and Occludin respectively (140, 141). Similarly, in humans, infection with T. trichiura and S. 
mansoni increased the expression of plasma fibronectin, another mesenchymal marker, and 
cellular vimentin respectively (142, 143).  
In addition to altering EMT, helminth infections may also impact cancer progression by causing 
aberrant changes in the cell cycle which can lead to uncontrolled proliferation and an 
accumulation of detrimental genetic mutations, both of which are hallmarks of cancer (144, 
145). In support of this, treatment with O. viverrini ES product or B. malayi altered the in vitro 
proliferation of fibroblasts and several human carcinoma cell lines respectively by modifying 
cell progression through G1 to S of the cell cycle (146, 147). 
Figure 1.9: Increased expression of mesenchymal markers and decreased expression of epithelial 




1.10 Aims and Objectives 
In this study, we used antigens derived from two STHs, the hookworm N. brasiliensis and the 
gastrointestinal nematode H. polygyrus, to identify how exposure to helminths may influence 
cancer development and progression.  
Hypothesis: Antigens derived from parasitic helminths will promote cancer development and 
progression in vitro and in vivo. 
Aim: To determine the impact of antigens derived from parasitic helminths on cancer 
development and progression in vitro and in vivo. 
This aim will be achieved through addressing the following objectives: 
Objective 1: Investigate the impact of helminth exposure on cervical cancer progression 
Objective 2: Investigate the impact of helminth antigens on CRC progression 





2. Materials and Methods 
2.1 Helminth Antigen Preparation 
2.1.1 Nippostrongylus brasiliensis L3 Antigen 
N. brasiliensis is a rodent nematode, which is commonly used to model infection with human 
hookworm. The lifecycle and immune response to this parasite has been well-characterised 






















L3s enter the blood 
vessels and migrate to the 
lungs 
L4s enter the airways, are 
coughed up, swallowed and 
enter the intestine 
Stage 3 larvae (L3) infect 
the host by penetrating 
the skin 
Wistar rat 
Adults cause tissue 
damage and inflammation 
and are later expelled by 
the host Th2 immune 
response 
L4s mature and produce eggs 
which are excreted in the 
faeces  
L3s break through the lung 
capillaries and mature to 
L4s in the parenchyma 
Larvae hatch and moult twice 
to the L3 stage 
Figure 2.1 The lifecycle of N. brasiliensis. 
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Wistar rats were infected subcutaneously with 500 L3 N. brasiliensis larvae and the faecal 
material collected over the next week. The faeces were mixed with charcoal, smeared onto 
dampened filter paper and stored in a dark, humid area for two weeks. During this period, the 
larvae were washed from the edge of the filter paper into distilled water containing 50μg/ml 
penicillin/streptomycin and fungizone. This mixture was left for one hour allowing the larvae to 
settle to the bottom of the container. The supernatant was then aspirated off, the larvae 
washed twice and subsequently concentrated into 2ml of distilled water. In order to disrupt the 
cellular membranes, the larvae were dipped into liquid Nitrogen (-195°C) before centrifugation 
at 2500 revolutions per minute (rpm) (700g). The supernatant, containing the water-soluble 
fraction of the L3 proteins, was collected and the protein concentration quantified using a 
nanodrop (Nanodrop Spectrophotometer ND-1000). It is undeniable that this preparation 
contains multiple antigens however for simplicity, it will from here on be referred to as N. 
brasiliensis L3 antigen. 
A nanodrop spectrophotometer is used to quantify the concentration and purity of a nucleic 
acid or protein sample. This is done by exposing it to a specific wavelength of ultraviolet (UV) 
light, which is absorbed by the sample. The more light absorbed by the sample the higher the 
concentration of the sample since less light will reach the photo-detector. This will result in a 
higher optical density (OD) being recorded. In the case of this study, the protein concentration 
of the helminth derived antigen preparations was measured at a wavelength of 280nm (A280) 
because this is the wavelength at which protein best absorbs UV light. 
2.1.2 Heligmosomoides polygyrus Antigen and HES 
H. polygyrus is a murine nematode which has been well-defined for use in both in vivo and in 
vitro murine studies (Figure 2.2) (148). Infection with H. polygyrus closely resembles that of 
human gastrointestinal nematode infections and was, therefore chosen for use in this study.  
H. polygyrus somatic antigen and H. polygyrus excretory-secretory products (HES) were 
prepared using the method described by Johnston et al (149). Male, 8-week-old, C57BL/6 
mice were infected with 400 L3 H. polygyrus larvae by gavage and on day 14 the mice were 
sacrificed. The upper portion of the gut, from the bottom of the stomach to the beginning of 
the cecum, was removed and drawn out to its full length. The gut was then cut along its length 
and scraped to remove the intestinal contents, including the adult H. polygyrus. As seen in 
Figure 2.3, the worms were then placed into muslin bags and secured to the edge of a funnel 
























The funnel was then filled with Hanks media (appendix 8.1) and the apparatus stored at 37°C 
for two hours with intermittent agitation. The worms were allowed to settle and then removed 
and placed in a 50ml falcon tube. The worms were washed six times with Hanks media, 
steeped in 10% Gentomycin and finally washed a further six times with Hanks media. The 
worms were then separated into T25 flasks containing H. polygyrus media (appendix 8.1). 
Twice a week, for three weeks, the medium was collected and replaced with fresh H. polygyrus 
media. The medium was then spun down, the supernatant sterile filtered (40µm) and stored 
at -20°C. A 3000MW filter (EMD Millipore™ PLTK04310), in an Amicon concentrator, was 
used to concentrate the medium and dialyse the resulting protein, glycoprotein mixture to 1X 
Figure 2.2 The lifecycle of H. polygyrus. 
C57BL/6 mouse 
Stage 3 larvae (L3) are 
ingested by the host L3s enter the small 
intestine 
Larvae hatch and moult twice 
to the L3 stage 
Adults cause tissue damage and 
inflammation and are later 
expelled by the Th2 immune 
response 
L3s penetrate through the 
wall of the small intestine 
into the submucosa  
Once matured, adults return to 
the lumen and produce eggs, 




Phosphate Buffered Saline (PBS) (appendix 8.4). The protein concentration of the resulting 









At the end of the three weeks the worms were collected and stored at -80°C. When required, 
the worms were defrosted, uniformly homogenized in PBS, centrifuged, the supernatant 
collected and sterile filtered (40µm). Once again, it is undeniable that this preparation contains 
multiple antigens however for simplicity, it will from here on be referred to as H. polygyrus 
antigen. A Bicinchoninic Acid (BCA) assay was used to quantify the protein concentration in 
the isolated H. polygyrus antigen. 
A BCA assay (Thermo Scientific Product #23227) is used to quantify the total protein 
concentration in a sample. The protein concentration is displayed as a change in colour from 
green to purple in proportion to the protein concentration, which can be measured using a 
spectrophotometer and compared to a protein standard of known concentration. 
2.1.3 Verification of HES Immune-Regulatory Effects 
HES is known to expand the mouse and human Foxp3+ regulatory T cell population through 
the action of the structurally distinct TGF-β mimic contained within it (16, 33). We therefore 
needed to ascertain whether the HES harvested for use in this study exhibited this immune-
regulatory property before being used in in vitro and in vivo experiments. To this end, the effect 
that the harvested HES had on the Foxp3+ T cell population and CD4+ T cell proliferation was 
determined. 
The spleen was removed from one female BALB/c mouse and passed through a cell separator 
(40µm) into Roswell Park Memorial Institute Medium-1640 (RPMI-1640) (appendix 8.2). The 
cell suspension was subsequently centrifuged for five minutes at 1500rpm (250g). The pellet 
Figure 2.3 H. polygyrus adult worm isolation. Muslin bags containing adult worms are secured to 




was then resuspended in 2ml Red Blood Cell lysis buffer for two minutes, topped up with RPMI 
and centrifuged for five minutes at 1500rpm. The cells were then resuspended at a density of 
107cells/ml in 2µM Carboxyfluorescein Succinimidyl Ester (CFSE) (Life Technologies C34554) 
in PBS and incubated in the dark for 20 minutes at 37°C. 
CFSE is a cell permeable fluorescent staining dye which can be used to monitor cell 
proliferation due to the progressive halving of the fluorescence intensity of the dye following 
each cell division (150). CFSE is light sensitive and, therefore all subsequent steps were 
carried out under the appropriate conditions. After 20 minutes, the tube was topped up with 
RPMI, to wash off excess CFSE and quench any remaining reaction and incubated for five 
minutes at 37°C before centrifuged for five minutes at 1500rpm. CFSE labelled cells were then 
plated at a density of 5x105 cells/100µl per well in a 96-well round-bottom plate. The plate was 
incubated for 72 hours at 37°C in the presence of 1µg anti-CD3 only or anti-CD3 plus 10µg 
HES (Figure 2.5A). 
After 72 hours the plate was centrifuged for two minutes at 1500rpm and the pellets 
resuspended in 200µl MACS buffer (appendix 8.1). A 1:200 dilution of Peridinin Chlorophyll 
Protein (PerCP)-labelled rat anti-mouse monoclonal CD4 (BD Bioscience, Clone RM4-5) was 
added to the relevant wells together with 1% rat serum and 1% FcɣRII/III to prevent non-
specific binding. The plate was then incubated for 20 minutes at 4°C. Wells were topped up 
with MACs buffer and the plate centrifuged for two minutes at 1500rpm. In order to access 
intracellular Foxp3, the cells were fixed (eBioscience Ref. 00-5523-00) for a minimum of 45 
minutes at 4°C following which the wells were topped up with Perm buffer (supplied in the 
Foxp3 Staining Buffer Set) and the plate centrifuged for two minutes at 1500rpm. Perm Buffer 
containing a 1:50 dilution of allophycocyanin (APC)-labelled rat anti-mouse monoclonal Foxp3 
(BD Bioscience, Clone FJK-16s) was then added to the relevant wells and the plate incubated 
for 30 minutes at 4°C. The buffer was then removed, fresh Perm buffer added, and the plate 
centrifuged for two minutes at 1500rpm. The pellets were then resuspended in MACs buffer 
in preparation for analysis on the Becton Dickinson (BD) LSR II Flow Cytometer. FlowJo 























This revealed that the Foxp3+ T cell population was significantly expanded in the anti-CD3 
plus HES stimulated CD4+ T cells compared to that of anti-CD3 only stimulated CD4+ T cells 
(Figure 2.5A and Figure 2.5B). Furthermore, significantly fewer CD4+ T cells underwent two 
and three cellular divisions when stimulated with anti-CD3 plus HES than that of anti-CD3 only 
stimulated CD4+ T cells (Figure 2.5C and Figure 2.5D).  
 
  
Figure 2.4: Gating strategy applied to obtain the Foxp3+ T cell population. Splenocytes from one 
female BALB/c mouse were seeded at a density of 5x105 cells per well in a 96-well round-bottom plate 
and cultured for 72 hours. CD4+ T cells were subsequently labelled and stimulated under different 










































































































Figure 2.5: HES induces Foxp3+ T cell population expansion and reduces CD4+ T cell 
proliferation. Cells from the spleen of one female BALB/c mouse were seeded at a density of 5x105
 
cells per well in a 96-well round-bottom plate, stimulated under different treatment conditions (1µg CD3 
or 1µg CD3 and 10µg HES) and cultured for 72 hours. A. Summary of the HES batches utilised and the 
percentage of Foxp3+ T cells induced by each. B. Splenocytes were stained appropriately and the 
Foxp3+ CD4+ T cell population present in each treatment condition were analysed using FlowJo Version 
10. C and D. CD4+ T cells were stained appropriately, labelled with CFSE and analysed using FlowJo 
Version 10. Analysis was performed using GraphPad 6.01 and a parametric unpaired t-test was 
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2.2 Limulus Amoebocyte Lysate (LAL) Assay 
The LAL assay (Pierce LAL Chromogenic Endotoxin Quantitation Kit, ThermoFisher Scientific 
88282) is used to measure the endotoxin concentration (EU/ml) in a given sample. This is 
achieved by measuring the presence a chromogenic signal, at 405nm, which is generated in 
the presence of endotoxins and compared to a standard curve created using an E. 
coli endotoxin standard.  
This assay was used to determine the endotoxin concentration in all helminth derived antigen 
preparations to ensure that any significant effects observed in subsequent experiments were 
due to the antigen and not an endotoxin contamination. 
2.3 Cell Line Culture 
Cervical cancer cell lines HeLa (HPV18 positive epithelial adenocarcinoma cells), Ca Ski 
(HPV16 positive epithelial epidermoid carcinoma cells) and C33-A (HPV negative epithelial 
carcinoma cells) and colorectal cancer cell lines CT26.WT (a murine N-nitroso-N-
methylurethane-(NNMU) induced, undifferentiated fibroblast colon carcinoma cell line) and 
HCT116 (a human epithelial colon carcinoma cell line) were purchased from the American 
Type Culture Collection (ATCC). HeLa and C33-A cells were maintained in Dulbecco’s-
Modified Eagle Medium (DMEM) (appendix 8.2), Ca Ski and CT26.WT cells were maintained 
in RPMI and HCT116 cells were maintained in McCoy’s Modified 5a medium (appendix 8.2).  
When needed, cells were retrieved from liquid Nitrogen and thawed in a 37°C waterbath. 
Thawed cells were resuspended in 4ml of the relevant medium and centrifuged for two minutes 
at 2500rpm. The supernatant was subsequently removed, and the pellet resuspended in 1ml 
of medium. The cell suspension was then plated into a T75 flask, containing 9ml of medium, 
and kept at 37°C in an atmosphere of 5% CO2 and 95% humidity. Once the cells had been 
passaged at least twice, to ensure stability, they were used in the various experiments. Cells 
were passaged, and the media replaced every 48-72 hours depending on confluency. 
2.4 Mycoplasma Testing 
Mycoplasma is a gram-negative bacterium, which lacks a cell wall and is more resistant to 
common antibiotics. For this reason, cells were regularly mycoplasma tested to ensure that all 
experimental results were due to the effect of the helminth derived antigens only. 
Cells were grown in a 35cm dish in antibiotic-free medium on a sterile coverslip for a minimum 
of 48 hours. After the incubation period, 1ml of fixative (appendix 8.3) was added to the dish 
for ten seconds, poured off and repeated. The dish was then rinsed three times with tap water 
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and once dried stained with 500µl of nucleic acid stain Hoechst No. 33258 (0.5μg/ml) for five 
seconds. The staining solution was poured off and the dish rinsed three times with tap water. 
The coverslip was then transferred to a microscope slide containing one drop of mounting fluid 
(appendix 8.3). Cells were subsequently viewed under a fluorescent microscope using the 
DAPI filter. The visualization of large nuclei (cell nuclei) surrounded by small nuclei 
(mycoplasma nuclei) was concluded as positive for mycoplasma. 
2.5 In vitro Assays 
2.5.1 Growth Curve Assay 
In order to determine the effect of helminth derived antigen on cancer cell proliferation, the 
short-term growth of cells was monitored over a 3-day period as previously described (151). 
The media was removed, and the cells lifted using 2ml of Trypsin- Ethylenediaminetetraacetic 
acid (EDTA) (appendix 8.4). Cells were resuspended in 4ml of medium for counting and 5x104 
cells were seeded per well, in triplicate, in a 24-well plate. N. brasiliensis L3 antigen (0.1µg or 
1 µg or 10µg), HES (10µg), H. polygyrus antigen (10µg) or 1X PBS was added to the required 
wells and the cells counted 24, 48 and 72 hours post-treatment. To do this, the cells in each 
well were trypsinised and resuspended in 300µl of medium per well and counted using a 
haemocytometer.  
To ensure that dead cells were excluded from the cells counts of all experiments, Trypan blue 
(Life Technologies, Ref. 15250-061) was used. Trypan blue is only able to permeate the 
membrane of dead cells and for this reason; all blue-stained cells were presumed dead and 
excluded from cell counts. 
2.5.2 Scratch Motility Assay 
A two-dimensional scratch motility assay was performed, in order to determine the effect of 
helminth derived antigen on cervical cancer cell migration (152). The media was removed, 
and the cells lifted using 2ml of Trypsin-EDTA. Cells were resuspended in 4ml of the relevant 
medium for counting and 5x104 (HeLa), 1x105 (Ca Ski) or 2x105 (C33-A) cells were seeded 
per well, in triplicate, in a 24-well plate and allowed to reach 100% confluency. The cells were 
subsequently serum starved in medium containing 0% FBS for 24 hours where after a sterile 
2µl pipette tip was used to make a vertical scratch in the cell monolayer of each well. The 
medium was then removed from each well followed by the addition of 500µl fresh medium and 
N. brasiliensis L3 antigen (0.1µg or 1µg or 10µg), HES (10µg), H. polygyrus antigen (10µg) or 











At each time point the total area of the scratch was imaged using ZoomBrowser Ex software 
with pictures being taken using a non-phase contrast lens at 10X magnification (Canon 
PowerShot S50). ImageJ Software (National Institute of Health, Bethesda, MD) was used to 
calculate the area of the scratch and to determine the total area migrated by the cells relative 
to the wound area at time zero hours. 
2.5.3 Transwell Migration Assay 
Transwell migration assays are used to determine the migratory response of cells when 
exposed to different treatments. Serum starved cells are placed on the upper surface of a cell 
permeable membrane in medium supplemented with a lower percentage of FBS, and medium 
containing a higher percentage FBS is placed below this. Cells that have migrated from the 
treatment containing upper chamber, towards the FBS rich medium in the lower chamber, 
adhere to the lower surface of the cell permeable membrane allowing them to be fixed, stained 
and quantified appropriately. 
An established transwell migration assay was performed in order to further characterise the 
effect of helminth derived antigen on cancer cell migration (152). This was achieved using 24-
well hanging-inserts fitted with an 8µm pore size membrane (Millicell Cell Culture Inserts 
Category No. MCEP24H48). Cells were cultured to 70% confluency in a 6cm dish and 
subsequently serum starved for 24 hours in medium supplemented with 0% FBS (HeLa, Ca 
Ski and C33-A) or 0.2% FBS (CT26.WT and HCT116). Cells were then lifted using 500µl 
Trypsin-EDTA and resuspended in 4ml of medium supplemented with 1% FBS for counting. 
500µl of medium supplemented with 10% FBS was placed into each well followed by the 
addition of the hanging-insert. A 250µl cell suspension containing 1x105 cells was then 
seeded, in triplicate, onto the apical surface of each hanging-insert together with N. brasiliensis 
L3 antigen (10µg), HES (10µg), H. polygyrus antigen (10µg) or 1X PBS and left to incubate 
for 24 hours (Figure 2.7). 
 
Figure 2.6 Two-dimensional scratch motility assay. A vertical scratch is made in the cell monolayer 
and wound closure monitored over an 8-hour period. Area migrated at T4 = Area at T0 – Area at T4; 










At the relevant time point the cells on the lower surface of the insert were fixed with 100% 
methanol for five minutes and stained with crystal violet for five minutes. The crystal violet was 
then washed off using distilled water and the plate left to dry overnight. 50% acetic acid was 
used to wash off the crystal violet from the bottom of the insert and the crystal violet washes 
transferred to corresponding wells of a 96-well plate. The absorbance of each well was then 
read at a wavelength of 595nm using a Rayto RT-2100C Microplate Reader. 
2.5.4 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Assay 
A MTT assay is a colourimetric assay used to measure cell viability. During this assay, yellow 
MTT is cleaved to purple formazan crystals in the mitochondria of metabolically active cells 
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Well of a 24-well plate 
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8µM Pore Membrane 
Figure 2.7: Transwell migration assay. Serum starved cells are placed onto the apical surface of a 
transwell hanging-insert containing medium supplemented with 1% FBS and N. brasiliensis L3 antigen 
(10µg), HES (10µg), H. polygyrus antigen (10µg) or 1X PBS. The insert is then placed into a 24-plate 
well containing medium supplemented with 10% FBS. Migrated cells adhere to the lower surface of the 
8µM pore cell permeable membrane and are subsequently fixed using methanol and stained with 
crystal violet. 50% acetic acid is used to wash off the crystal violet stain and the absorbance of each 
well’s crystal violet wash is read at a wavelength of 595nm. 
Figure 2.8: MTT reaction. The formation of insoluble formazan crystals from yellow tetrazolium MTT 
due to active mitochondrial reductase enzymes present in viable cells.  
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This reduction reaction is only possible in living cells due to their active mitochondrial 
reductase enzymes. A solubilizing solution, containing acidified isopropanol, is added to 
dissolve the insoluble purple MTT formazan crystals thus allowing the wavelength of the purple 
solution to be measured by a spectrophotometer at a wavelength of 595nm. For this reason, 
the number of viable cells is directly proportional to both the ability of the cells to convert the 
yellow salt into a purple solution and the spectrophotometric absorbance reading of the purple 
solution.  
To determine colorectal cancer cell viability following treatment with both HES and H. 
polygyrus antigen, a MTT Cell Proliferation Kit (Roche, 11465007001) was used. The media 
was removed, and the cells lifted using 2ml of Trypsin-EDTA. Cells were resuspended in 4ml 
of the relevant medium for counting and 8x103 cells were seeded per well, in quadruplicate, in 
a 96-well plate and HES (10µg), H. polygyrus antigen (10µg) or 1X PBS added to each of the 
required wells for 24 hours. Post-incubation, 10µl of MTT reagent (0.5mg/ml) was added to 
each well for four hours followed by the addition of 100µl of solubilisation solution. After an 
overnight incubation, the absorbance reading of each well was read at a wavelength of 595nm. 
The absorbance of medium only wells was subtracted from the absorbance of sample wells 
to obtain a final absorbance reading. 
2.5.5 Bromodeoxyuridine (BrdU) Incorporation Assay 
BrdU is a synthetic nucleoside that is an analogue of the pyrimidine deoxynucleoside 
thymidine. BrdU is often used in the detection of proliferating cells because it can be 
incorporated into the newly synthesized DNA of replicating cells as a substitute 
for thymidine. Antibodies specific for BrdU can then be used to indicate cells that were actively 









Figure 2.9: BrdU Incorporation Assay. BrdU, a synthetic analogue of thymidine, can be used in the 
detection of proliferating cells due to its ability to be incorporated into newly synthesized DNA. BrdU 
specific and fluorochrome labelled antibodies can then be used to indicate cells that were actively 
replicating their DNA at the time of BrdU addition.  
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A BrdU incorporation assay was used in order to determine the effect of HES and H. polygyrus 
antigen on CT26.WT proliferation. To this end, 2x105 cells were seeded on a sterile glass 
coverslip in a 35mm dish, treated with HES (10µg), H. polygyrus antigen (10µg) or 1X PBS 
and allowed to adhere overnight. Cells were then incubated in medium containing 10µm BrdU 
for eight hours followed by fixation with Carnoy’s fixative (appendix 8.4) for 20 minutes at -
20°C. For immunostaining, cells were incubated in 2M HCl (appendix 8.4) for one hour at 37°C 
and then neutralized in 0.1M pH 8.5 borate buffer (appendix 8.4). Cells were washed with 
PBS/ 0.5% Tween20 (appendix 8.4) and incubated for 30 minutes at 37°C in blocking buffer 
(5% sheep serum in PBS/ 0.5% Tween20). BrdU was detected with an anti-BrdU mouse 
monoclonal antibody (6µg, Roche, Germany) for 30 minutes at 37°C, followed by a secondary 
IgG coupled to Alexa488 (1:1000, Molecular Probes, USA) for 30 minutes at 37°C. Cells were 
washed with PBS/ 0.5% Tween20, incubated in 1µg DAPI (4',6-diamidino-2-phenylindole) for 
ten minutes at room temperature, in the dark, and washed with PBS/ 0.5% Tween20. The 
coverslips were then mounted onto microscope slides, stored in the dark in a humidifying 
chamber overnight at 4°C and visualized by fluorescence microscopy using an Axiovert 
Fluorescent microscope (Zeiss, Germany). 
2.5.6 Western Blotting 
2.5.6.1 Protein Extraction 
To determine the effect of helminth derived antigen on the expression of cancer Epithelial- 
Mesenchymal Transition (EMT) markers and cell cycle regulator proteins, western blotting was 
performed. The media was removed, and cells lifted using 2ml of Trypsin-EDTA. Cells were 
resuspended in 4ml of medium for counting and 2x105 (HeLa, CT26.WT and HCT116) or 
3.5x105 (C33-A) cells were seeded per well in a 6-well plate and N. brasiliensis L3 antigen 
(10µg or 50µg), HES (10µg), H. polygyrus antigen (10µg) or 1X PBS added to each of the 
required wells. At the relevant time point the protein was harvested from each well. To do this 
the media from each well was removed, cells lifted using 500µl Trypsin-EDTA, resuspended 
in 1ml of medium and centrifuged for two minutes at 2500rpm. The supernatant was 
subsequently removed, and the pellet resuspended in Sodium-Dodecyl-Sulphate 
Polyacrylamide Gel Electrophoresis (SDS-Page) buffer/boiling blue (appendix 8.5). The 
harvested protein was placed in a 100°C heating block for 10 minutes and stored at -20°C 
until required.  
2.5.6.2 SDS-PAGE 
SDS-PAGE was used to separate the proteins in each sample on 1.5mm 8% resolving gels 
(15% for p21 only) with a 4% stacking gel (appendix 8.5). Gels were made in a BioRad Mini 
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PROTEAN© 3 casting apparatus and placed in the BioRad running tank filled with 1X running 
buffer (appendix 8.5). Equal amounts of sample were loaded into each lane and 5μl of the 
Thermo Scientific PageRulerTM Prestained Protein Marker (Fermentas, USA) (appendix 8.5) 
was loaded into its own lane to assist in determining the relative size of the proteins following 
separation. The running apparatus was connected to the Biorad Powerpack 200 and 
electrophoresis occurred at 120 Volts, 40 Watts and 0.35 Amperes. The time of the run was 
dependent on the size of the protein being detected, with smaller proteins requiring less time 
to separate. 
2.5.6.3 Transfer  
Following electrophoresis, the separated proteins were transferred onto a nitrocellulose 
membrane (Amersham, GE Healthcare, Life Sciences, Germany). This was achieved by 
placing the gel into a transfer cassette containing sponges, Whatman filter paper, the resolving 
portion of the gel and the nitrocellulose membrane pre-soaked in 1X transfer buffer (appendix 
8.5). This set-up was then placed into the transfer unit of the Biorad Mini PROTEAN© 3 
transfer tank to ensure that the negatively charged proteins moved from the gel onto the 





To prevent overheating, an ice pack was placed in the tank and the tank was filled with cooled 
1X transfer buffer. The transfer apparatus was connected to the Biorad Powerpack 200 and 
protein transfer took place at 100 Volts, 40 Watts and 0.35 Amperes for two hours. 
2.5.6.4 Detection 
Following transfer, the nitrocellulose membrane was blocked for one hour at room temperature 
and then probed with the appropriate primary antibodies overnight at 4oC with continuous 
shaking. Membranes were washed at 2X five-minute and 2X ten-minute intervals and 
incubated with the respective secondary antibody: horseradish peroxidase-conjugated anti-
rabbit or anti-mouse (1:5000) (BioRad, Hercules, CA, USA) for one hour at room temperature. 
The membrane was then washed as previously described and visualised by enhanced 
Figure 2.10: Western blot transfer set-up. For the separated proteins to be correctly transferred from 
the SDS-PAGE gel onto the nitrocellulose membrane the orientation of the above set-up is essential. 
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chemiluminescence (ECL) by the addition of SuperSignal West Pico Chemiluminescent 
Substrate (Pierce, Rockford, IL, USA) or WesternBright (Advansta, USA). A 1:1 ratio of 
detection reagent A and detection reagent B was used per blot (total detection reagent volume 
= length of blot and breadth of blot x 0.1ml) and left to incubate on the nitrocellulose membrane 
for five minutes. The membrane was then sealed between two acetate sheets. Once the 
detection reagents meet the enzyme-conjugated secondary antibody, on the nitrocellulose 
membrane, light is emitted. This occurs due to the presence of the substrate for horseradish 
peroxidase in the detection reagents and, therefore oxidation of the substrate by the enzyme 











Membranes were exposed to autoradiography film and the chemiluminescent signal captured 
by developing and fixing the blot. ImageJ was used to perform densitometric analysis with the 
readings normalised to the p38 loading control.  
The primary antibodies used were as follows (appendix 8.5):  
p38 (38kDa): The nitrocellulose membrane was blocked in 5% fat free milk in 1X PBS/0.1% 
Tween (PBS/T) and incubated with its’ primary antibody (1:5000 rabbit polyclonal anti-p38) 
(Sigma-Aldrich, USA) in PBS/T only.  
p21 (21kDa): The nitrocellulose membrane was blocked and incubated with its’ primary 
antibody (1:200 mouse monoclonal anti-p21) (Santa Cruz, USA) in 5% fat free milk in 1X 
PBS/0.1% Tween (PBS/T). 
Figure 2.11: Protein detection by enhanced chemiluminescence. The primary antibody, specific to 
the protein of interest, binds to its target on the nitrocellulose membrane. An enzyme-conjugated 
secondary enzyme, raised against the animal that the primary antibody was raised in, binds to the 
primary antibody. The enzyme substrate is added directly onto the nitrocellulose membrane allowing for 




p53 (53kDa): The nitrocellulose membrane was blocked and incubated with its’ primary 
antibody (1:100 mouse monoclonal anti-p53) (Santa Cruz, USA) in 5% fat free milk in 1X 
PBS/0.1% Tween (PBS/T). 
Vimentin (57.5kDa): The nitrocellulose membrane was blocked and incubated with its’ primary 
antibody (1:1000 rabbit polyclonal anti-vimentin) (Cell Signaling Technology, USA) in 5% 
Bovine Serum Albumin (BSA) in TBS/T. 
β-catenin (94kDa): The nitrocellulose membrane was blocked and incubated with its’ primary 
antibody (1:500 mouse monoclonal anti-β-catenin) (Thermo Fisher Scientific) in 5% fat free 
milk in 1X PBS/0.1% Tween (PBS/T). 
N-cadherin (140kDa): The nitrocellulose membrane was blocked and incubated with its’ 
primary antibody (1:1000 mouse polyclonal anti-N-cadherin) (Cell Signalling Technology, 
USA) in 5% fat free milk in 1X TBS/0.1% Tween (TBS/T). 
2.5.7 Flow Cytometry on Cell-Surface Vimentin Expression 
To determine the effect of N. brasiliensis L3 antigen on HeLa cell-surface vimentin expression, 
the appropriately stained cells were analysed by flow cytometry. The media was removed, and 
the cells lifted using 2ml of Trypsin-EDTA. Cells were resuspended in 4ml of the DMEM for 
counting and 1x105 cells were seeded per well, in quadruplicate, in a 24-well plate. N. 
brasiliensis L3 antigen (10µg or 50µg), lipopolysaccharide (LPS) (1µg) or 1X PBS was added 
to each of the required wells and the cells harvested at 12 hours post-treatment. To do this 
the cells in each well were lifted using Lidocaine-EDTA (appendix 8.4), to retain surface 
molecule integrity, and resuspended in 400µl of MACS buffer per well. Samples were 
centrifuged for five minutes at 1500rpm and 200µl of the supernatant removed. The pellet was 
then resuspended in the remaining 200µl of MACS buffer and the cell suspension added to 
individual wells of a 96-well round-bottom plate. The plate was then centrifuged for five 
minutes at 1500rpm, the supernatant removed, and the pellet resuspended in 20µl of MACS 
buffer containing a 1:50 dilution of rabbit polyclonal anti-vimentin (Santa Cruz Biotechnology, 
Clone H84) and R-phycoerythrin (PE)-conjugated donkey anti-rabbit IgG (Jackson 
ImmunoResearch Laboratories, Inc). The plate was subsequently incubated for 20 minutes at 
4°C. Wells were then topped up with MACs buffer and the plate centrifuged for two minutes 
at 1500rpm. The pellets were resuspended in 200µl of MACs buffer ready for analysis on the 
BD LSR II Flow Cytometer. FlowJo Version 10 was used to analyse the data according to the 





















2.5.8 HPV16 Pseudovirion Internalisation Assay 
In order to determine the effect of N. brasiliensis L3 antigen on HPV internalisation in HeLa 
cells, a HPV pseudovirion internalisation assay was performed whereby cells were exposed 
to fluorochrome labelled HPV16 pseudovirions and analysed by flow cytometry. HPV16 
pseudovirion preparation, labeling, and quality controls were performed as previously 
described (155).  
The media was removed, and the cells lifted using 2ml of Trypsin-EDTA. Cells were 
resuspended in 4ml of DMEM for counting and 1x105 cells were seeded per well, in 
quadruplicate, in a 24-well plate. N. brasiliensis L3 antigen (10µg or 50µg) or 1X PBS was 
added to each of the required wells for 12 hours. After this incubation period, 400ng of 
Alexa488 labelled HPV16 pseudovirions were added to each well (4pg per cell) and incubated 
for one hour at 4°C, to allow for pseudovirion attachment, and then 30 minutes at 37°C, to 
allow for pseudovirion internalisation. Cells were then lifted using Trypsin-EDTA, to ensure the 
removal of any surface-bound pseudovirions and harvested in 200µl of MACS buffer per well 
Figure 2.12: Gating strategy applied to obtain the cell-surface vimentin positive population. A. 
Cells were seeded, in quadruplicate, at a density of 1x105 cells per well in a 24-well plate and treated 
with 10µg or 50µg N. brasiliensis L3 antigen or 1X PBS. Cells were incubated for 12 hours before 
harvesting in MACS buffer. B. Population of cells which have been stained with secondary antibody only. 
This control was used to determine the positively stained cell-surface vimentin population. Analysis 
















ready for analysis on the BD LSR II Flow Cytometer. FlowJo Version 10 was used to analyse 















2.6 In vivo Experiments 
2.6.1 Mice  
Unless stated otherwise, 6-10-week-old female BALB/c mice were used in all experiments. 
Mice were either bred in house (animal research performed at The University of Cape Town) 
or purchased from Charles River (animal research performed at Cardiff University). 
Section 20 dispensation to carry out animal research at the University of Cape Town was 
granted by the South African Department of Agriculture Fisheries and Food and by the UCT 
Health Sciences Animal Ethics Committee (Project number 014/027 and 015/001). All 
procedures were performed by researchers accredited by the South African Veterinary 
Council. Permission to perform animal research at Cardiff University was granted by the Home 
A 
B 
Figure 2.13: Gating strategy applied to obtain the HPV16 pseudovirion positive population. A. 
Cells were seeded, in quadruplicate, at a density of 1x105 cells per well in a 24-well plate and treated 
with 10µg or 50µg N. brasiliensis L3 antigen or 1X PBS. Cells were incubated for 12 hours before the 
addition of 400ng of HPV16 pseudovirions per well for 1 hours at 4°C and 30 minutes at 37°C. Cells 
were subsequently harvested in MACS buffer. B. Population of HeLa cells which were not treated with 
Alexa488 labelled HPV16 pseudovirions. This control was used to generate a gate for HPV16 













Office and performed under protocol 5 (Immunotherapy of Primary Tumours), project number 
30/3428 (Induction of Anti-tumour Immunity). 
2.6.2 Western Blotting on Murine Female Genital Tract (FGT) Tissue 
To synchronize the estrous cycles, mice were treated with 2mg Medroxyprogesterone Acetate 
(Depo Provera®) subcutaneously. A week later, mice were infected subcutaneously with 500 
L3 N. brasiliensis larvae and killed at day nine post-infection (Figure 2.14). The entire FGT 





Tissue samples were sonicated until uniformly homogenized and centrifuged to remove 
unwanted debris. The protein concentration of the supernatant was determined using a BCA 
assay and 20µg of protein per sample was used to run on a SDS-PAGE gel as previously 
described. 
2.6.3 Colorectal Cancer Model 
CT26.WT cells were utilized in an in vivo model to investigate the effect of HES and H. 
polygyrus antigen on colorectal cancer tumour development and progression. To achieve this, 
CT26.WT cells were cultured in vitro for a maximum of seven days and passaged at least 
twice before being injected subcutaneously into the left flank of mice. Each mouse received 
5x105 cells in a total volume of 100µl of PBS with either HES (10µg), H. polygyrus antigen 
(10µg) or 1X PBS. Tumour width and height were regularly measured using digital calipers, 
and the tumour volume calculated according to the equation: 
Volume = 0.5 * (Height x Width2). 
Two weeks later, mice were sacrificed and the tumours, inguinal draining (dLN) and non-
draining lymph nodes (ndLN) removed. The lymph nodes were passed through a cell 
separator (70µm) into RPMI and the cell suspension centrifuged for five minutes at 1500rpm. 
The pellet was resuspended in 150µl of RPMI and 100µl of this placed into individual wells of 
a 96-well round-bottom plate. 100µl of 50ng/ml Phorbol Myristate Acetate (PMA) (EMD 
Millipore) plus 50ng/ml of ionomycin (Sigma-Aldrich, USA) was added to each well and the 
plate was left to incubate for four hours at 37°C. PMA (a protein kinase C activator) and 
Figure 2.14: Experimental setup followed to determine the effect of N. brasiliensis infection on 
EMT marker expression in the mouse FGT. 
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ionomycin (a calcium ionophore) are used to stimulate the production of intracellular cytokines 
by lymphocytes. One hour into the stimulation a 1:1000 dilution of Brefeldin A (Brev A) (Sigma-
Aldrich, USA) was added to each well. Brev A inhibits protein transport, in this case the newly 
produced cytokines, from the endoplasmic reticulum to the Golgi apparatus and, therefore 
prevents release from the cell allowing the proteins to be stained and analysed appropriately 
(156). 
After stimulation, the plate was centrifuged for three minutes at 1750rpm, the supernatant 
removed and a 1:10 dilution of live/dead aqua stain (Thermo Fisher Scientific) added to each 
well. The plate was then incubated for 15 minutes at room temperature. 150µl of FACS buffer 
(appendix 8.6) was added to each well and the plate centrifuged for three minutes at 1750rpm. 
50µl containing a 1:100 dilution of FcɣRII/III (eBioscience) was added to each well and the 
plate placed at 4°C for 15 minutes. 50µl containing a 1:100 dilution of Phycoerythrin Cyanine 
7 (PeCy7)-labelled rat anti-mouse monoclonal CD3 (BioLegend, Clone 17A2), Brilliant Violet 
(BV) 421-labelled rat anti-mouse monoclonal CD8 (BioLegend, Clone 53-6.7) and BV605-
labelled rat anti-mouse monoclonal CD4 (BioLegend, Clone GK1.5) was added to each well. 
The plate was then incubated for 30 minutes at 4°C. Wells were subsequently topped up with 
FACS buffer and the plate centrifuged for three minutes at 1750rpm. The cells were then fixed 
(eBioscience Ref. 00-5523-00) overnight at 4°C. 
The plate was centrifuged for three minutes at 1750rpm and 100µl of Perm buffer (supplied in 
the Foxp3 Staining Buffer Set) was added to each well. 50µl containing a 1:100 dilution of 
FcɣRII/III was added to each well and the plate placed at 4°C for 15 minutes. 50µl containing 
a 1:100 dilution of APC-labelled rat anti-mouse monoclonal Foxp3 (BD Bioscience, Clone FJK-
16s) was then added to each well. The plate was then incubated for 30 minutes at 4°C and 
subsequently centrifuged for three minutes at 1750rpm. The cells were then washed once with 
Perm buffer and twice with FACS buffer for three minutes at 1750rpm per wash. The pellets 
were then resuspended in 200µl of FACS buffer in preparation for analysis on the ACEA 
Novocyte. FlowJo Version 10 was used to analyse the data according to the gating strategy 




















The CT26.WT tumours were passed through a cell separator (70µm) into RPMI and the cell 
suspension centrifuged for five minutes at 1500rpm. The pellet was resuspended in 150µl of 
RPMI and 100µl of this placed into individual wells of a 96-well round-bottom plate. The plate 
was then centrifuged for three minutes at 1750rpm, the supernatant removed and a 1:10 
dilution of live/dead aqua stain was added to each well. The plate was then incubated for 15 
minutes at room temperature. 150µl of FACS buffer was added to each well and the plate 
centrifuged for three minutes at 1750rpm. 50µl of a 1:100 dilution of FcɣRII/III was added to 
each well and the plate placed at 4°C for 15 minutes. 50µl containing a 1:100 dilution of 
BV421-labelled rat anti-mouse monoclonal Ly6C (BioLegend, Clone HK1.4), FITC-labelled rat 
anti-mouse monoclonal Ly6G (BioLegend, Clone 1A8), PerCpCy5.5-labelled rat anti-mouse 
monoclonal CD11b (BioLegend, Clone M1/70) and BV605-labelled mouse anti-rat monoclonal 
CD4 (BioLegend, Clone GK1.5) was added to each well. The plate was then incubated for 30 
minutes at 4°C. Wells were subsequently topped up with FACS buffer and the plate 
centrifuged for three minutes at 1750rpm. The cells were then fixed (eBioscience Ref. 00-
5523-00) overnight at 4°C. 
The plate was centrifuged for three minutes at 1750rpm and 100µl of Perm buffer was added 
to each well. 50µl containing a 1:100 dilution of FcɣRII/III was added to each well and the plate 
placed at 4°C for 15 minutes. 50µl containing a 1:100 dilution of APC-labelled rat anti-mouse 
monoclonal Foxp3 (BD Bioscience, Clone FJK-16s) was added to each well. The plate was 
Figure 2.15: Gating strategy applied to cells of the draining (dLN) and non-draining (ndLN) 
lymph nodes. The dLN and ndLN were removed from CT26.WT tumour bearing mice, the cells seeded 
in a 96-well round-bottom plate and labelled and fixed appropriately. Analysis was performed using 

















then incubated for 30 minutes at 4°C and subsequently centrifuged for three minutes at 
1750rpm. The cells were then washed once with Perm buffer and twice with FACS buffer for 
three minutes at 1750rpm per wash. The pellets were then resuspended in 200µl of FACs 
buffer in preparation for analysis on the ACEA Novocyte. FlowJo Version 10 was used to 












Cell counts were performed on all samples using the ACEA Novocyte. Propidium Iodide 
(Sigma-Aldrich, USA) was used to exclude dead cells. PI is a fluorescent intercalating 
agent that is able to cross the membrane of dead cells making it possible to distinguish 
between viable and dead cells (157). 
2.6.4 The Effect of HES on Colitis-Associated Colorectal Cancer (CAC) Development  
When introduced in combination, the carcinogen azoxymethane (AOM) and inflammatory 
agent dextran sulphate sodium (DSS) are able to model the development of CAC in vivo (158). 
Importantly, when placed on DSS and a diet high in linoleic acid mice are at an increased risk 
of developing colitis and consequently, when used in conjunction with a carcinogen, colorectal 
cancer development. This is due to nano-lipocomplex formation between DSS and medium-
chain-length fatty acids present in the colon which are thought to activate intestinal 
inflammatory pathways (159). In order to determine whether HES is able to affect the 
development of CAC, mice were placed on AIN-76A food (a rodent diet high in linoleic acids) 
for one week and the experimental setup depicted in Figures 2.17 followed. 
Figure 2.16: Gating strategy applied to CT26.WT tumour cells. CT26.WT tumours were removed 
from mice, the cells seeded in a 96-well round-bottom plate and labelled and fixed appropriately. 





















The weight of each mouse was monitored daily and on day 15 the mice were sacrificed, and 
the colon and spleen harvested. The length of the colon was measured from the end of the 
cecum to the rectum and a portion placed in 4% paraformaldehyde (appendix 8.6) in 
preparation for histological processing. The spleen was weighed and stored in MACS buffer 
for further processing. 
Each spleen was passed through a cell separator (40µm) into RPMI and the cell suspension 
centrifuged for five minutes at 1500rpm. The pellet was then resuspended in 2ml Red Blood 
Cell lysis buffer for two minutes, topped up with RPMI and centrifuged for five minutes at 
1500rpm. 1x105 cells were seeded per well in a 96-well round-bottom plate and a 1:200 dilution 
of Alexa700-labelled rat anti-mouse monoclonal CD3 (BD Bioscience), PerCpCy5.5-labelled 
rat anti-mouse monoclonal CD4 (BD Bioscience), BV421-labelled rat anti-mouse monoclonal 
CD11b (BD Bioscience), PE-labelled rat anti-mouse monoclonal SiglecF (BD Bioscience), 
APC-labelled rat anti-mouse monoclonal Ly6G (BD Bioscience) and APC-Cy7-labelled rat 
anti-mouse monoclonal Ly6C/G-Gr1 (BD Bioscience) was added to the relevant wells together 
with 1% rat serum and 1% FcɣRII/III. The plate was then incubated for 30 minutes at 4°C. 
Wells were then topped up with MACs buffer and the plate centrifuged for two minutes at 
1500rpm. The pellets were then resuspended in MACs buffer in preparation for analysis on 
the BD LSR II Flow Cytometer. FlowJo Version 10 was used to analyse the data according to 
the gating strategy depicted in Figure 2.18.  
  
Figure 2.17: Experimental setup followed to determine the effect of HES on the development of 

















2.6.5 The Effect of the TGF-β Mimic Contained in HES on CAC Development in vivo 
In order to determine whether the TGF-β mimic contained within HES is able to affect the 
development of CAC, mice were placed on AIN-76A for one week and the experimental setup 






SB-431542 (Sigma-Aldrich - S4317) is a small molecule inhibitor of the TGF-β type I receptor 
(160). By inhibiting this receptor, SB-431542 prevents the phosphorylation of Smad2/3, which 
is then unable to form a complex with Smad4 and translocate into the nucleus. Ultimately, 
gene expression induced by TGF-β signaling does not occur (Figure 2.20). 
Figure 2.19: Experimental setup followed to determine the effect of the TGF-β mimic in HES on 
the development of colitis-associated colorectal cancer (CAC).   
Figure 2.18: Gating strategy applied to splenocytes. Cells from the spleen were seeded at a density 
of 1x10
6
 cells per well in a 96-well round-bottom plate and labelled and fixed appropriately. Analysis 































The weight and distress scores (Figure 2.21) of each mouse was monitored daily and on day 
15 the mice were sacrificed, and the colon and spleen harvested. The length of the colon was 
measured from the end of the cecum to the rectum and the spleen was weighed and stored 
in MACS buffer for further processing. FlowJo Version 10 was used to analyse the data 













Figure 2.21: Criteria used to calculate the total distress score for each mouse. Adapted from 
Professor Awen Gallimore’s laboratory at Cardiff University.   
Figure 2.20: SB-431542 method of action. Small molecule inhibitor, SB-431542, inhibits the TGF-β 
type I receptor.  This prevents the phosphorylation of Smad2/3 and complex formation with Smad4, 















2.7 Statistical Analyses 
Data were assessed for normality and equal variance and were log transformed if required 
using the GraphPad Prism 6.01 software (La Jolla, CA). For comparison between two groups, 
an unpaired t-test was used; where more than three groups were being tested, a parametric 
two-way or one-way analysis of variance with multiple comparisons was used. Error bars 









Figure 2.22: Gating strategy applied to splenocytes. Cells from the spleen were seeded at a density 
of 1x106 cells per well in a 96-well round-bottom plate and labelled and fixed appropriately. Analysis 


















3.1 Investigating the Effect of Parasite Antigen on Cervical Cancer Behaviour in vitro 
The impact of exposure to soil-transmitted helminths (STH) on cervical cancer cell growth, 
and migration is unknown. To this end, in vitro assays were performed investigating the effect 
of different parasite antigens on cervical cancer behaviour. 
3.1.1 Nippostrongylus brasiliensis L3 Antigen Does Not Affect HeLa Cell Proliferation 
The Human Papillomavirus type 18 (HPV18) positive cervical cancer cell line, HeLa, was 
exposed to a titration of N. brasiliensis L3 antigen concentrations and the cell proliferation 
monitored by counting cells over a 3-day period using a haemocytometer. When compared to 
untreated cells, N. brasiliensis L3 antigen did not have a significant effect on HeLa cell 
proliferation at any of the time points or concentrations tested (Figure 3.1).  
3.1.2 N. brasiliensis L3 Antigen Significantly Reduces HeLa Cell Migration and 
Expression of EMT Markers  
The possibility was considered that while N. brasiliensis L3 antigen did not affect HeLa cell 
proliferation, it may influence cell migration. To address this, HeLa cells were treated with N. 
brasiliensis L3 antigen and two-dimensional scratch motility and transwell migration assays 
were performed.  
Results from both assays indicated that N. brasiliensis L3 antigen decreased HeLa cell 
migration. Indeed, in the two-dimensional scratch motility assay, 10µg of N. brasiliensis L3 
antigen significantly decreased HeLa cell migration at 8 hours post-wound formation (Figure 
3.2A and Figure 3.2B). Similarly, the transwell migration assay revealed a 1.36-fold decrease 
in the migration of HeLa cells treated with 10µg of N. brasiliensis L3 antigen compared to that 
of untreated cells (Figure 3.2C).  
To determine whether this effect was hookworm specific, HeLa cells were exposed to antigen 
derived from the adult stage of the solely gastrointestinal nematode H. polygyrus or its 
excretory-secretory product (HES). Notably, no significant effect on the migration of H. 
polygyrus antigen or HES treated HeLa cells was observed (Figure 3.2D), suggesting that the 
inhibitory effect of N. brasiliensis L3 antigen on HeLa cell migration is hookworm dependent. 
It was speculated that N. brasiliensis L3 antigen may be inhibiting HeLa cell migration by 
repressing Epithelial-Mesenchymal Transition (EMT) markers. To investigate this, levels of 














treated with or without N. brasiliensis L3 antigen. p38 was used throughout this study as a 
loading control in western blot analyses because although its activity is modulated by 
phosphorylation, total levels of this protein remain unchanged in response to stimuli (161). 
The results revealed that the observed reduction in HeLa cell migration was indeed associated 
with a decrease in the expression of the EMT markers vimentin and N-cadherin (Figure 3.3).  
3.1.3 N. brasiliensis L3 Antigen Significantly Reduces Ca Ski Cell Migration 
To investigate whether N. brasiliensis L3 antigen could also inhibit the migratory ability of other 
cervical cancer cells i.e. that the effect seen was not specific to HeLa cells, the above 
experimental conditions and migration assays were repeated for the Human Papillomavirus 
type 16 (HPV16) positive cervical cancer cell line Ca Ski. Indeed, results from the two-
dimensional scratch motility assay revealed that 10µg of N. brasiliensis L3 antigen significantly 
decreased Ca Ski cell migration at 4 and 8 hours post-wound formation (Figure 3.4A and 
Figure 3.4B). Furthermore, albeit not significant, when treated with 10µg of N. brasiliensis L3 
antigen, Ca Ski cell migration was also reduced in the transwell migration assay (Figure 3.4C). 
The impact of N. brasiliensis L3 antigen on the EMT markers vimentin and N-cadherin in Ca 
Ski cells was also explored by western blotting as described for the HeLa cells.  
 
 
Figure 3.1: N. brasiliensis L3 antigen does not affect HeLa cell proliferation. Cells were seeded in 
triplicate at a density of 5x104 cells per well in a 24-well plate and treated with 0.1µg, 1µg or 10µg N. 
brasiliensis L3 antigen or 1X PBS. Growth curve analyses were performed over a 3-day period by 
harvesting trypsinised cells and counting the cells using a haemocytometer. This figure shows pooled 
data from two independent experiments each performed in triplicate. The data were analysed using 
GraphPad Prism 6.01 and a parametric unpaired t-test was performed. Error bars represent Standard 
Error of the Mean. 
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Figure 3.2: N. brasiliensis L3 antigen decreases HeLa cell migration. A and B. Migration was 
measured using a two-dimensional scratch motility assay. 5x104 cells were seeded per well in a 24-well 
plate and allowed to reach confluency. Cells were treated with 0.1µg, 1µg or 10µg N. brasiliensis L3 
antigen or 1X PBS and a sterile 2µl pipette tip was used to form a linear wound in the cell monolayer. 
Cells were imaged at 0, 4 and 8 hours post-wound formation with the total area migrated calculated 
relative to wound area at time 0 hours. C. Serum starved cells were seeded at a density of 1x105 cells 
per well into a 24-well transwell hanging-insert containing DMEM supplemented with 1% FBS and 10µg 
N. brasiliensis L3 antigen or 1X PBS. Each insert was then placed individually into a well containing 
DMEM supplemented with 10% FBS. Migrated cells, which had adhered to the lower surface of the 8µm 
membrane, were fixed with methanol and stained with crystal violet. 50% acetic acid was used to wash 
off the crystal violet stain and the absorbance of each well was read at a wavelength of 595nm. D 
Migration was measured using a two-dimensional in vitro scratch motility assay as described for A and 
B. using 10µg HES or 10µg H. polygyrus antigen. All the panels in this figure represent pooled data 
from three independent experiments each performed in triplicate. The data were analysed using 
GraphPad Prism 6.01 and a parametric unpaired t-test was performed. C. Pooled data was log 
transformed before performing a parametric unpaired t-test.  *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. 
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However, despite numerous attempts the results were inconsistent and are, therefore not 
included in the thesis. Possible reasons for this are commented on in the Discussion. 
3.1.4 N. brasiliensis L3 Antigen Significantly Reduces C33-A Cell Migration and 
Expression of EMT Markers 
The HeLa and Ca Ski cervical cancer cell lines are HPV positive and it was, therefore of 
interest to determine whether the HPV status impacts the effects of N. brasiliensis L3 antigen 
on cervical cancer cell migration. To address this, C33-A HPV negative cervical cancer cells 
were exposed to the N. brasiliensis L3 antigen and their migration was measured by the two-
dimensional scratch motility and transwell migration assays. Indeed, the results from both 
assays show that the migration of C33-A cells was significantly inhibited following N. 
brasiliensis L3 antigen treatment (Figure 3.5A - 3.5C). Interestingly, C33-A cells appear to be 
more sensitive to N. brasiliensis L3 antigen as even the lower concentrations of antigen used 
in the two-dimensional scratch motility assay significantly reduced cell migration at 4 and 8 
hours post wound-formation (Figure 3.5B).  
Furthermore, as observed in the HeLa cells, both 10µg and 50μg N. brasiliensis L3 antigen 
reduced the expression of vimentin and N-cadherin in C33-A cells (Figure 3.6). Together 
these results show that N. brasiliensis L3 antigen reduces cervical cancer cell migration 
independent of HPV status by targeting EMT makers.  
 
Figure 3.3: N. brasiliensis L3 antigen decreases levels of EMT marker expression in HeLa cells. 
Cells were seeded at a density of 2x105
 
cells per well in a 6-well plate and treated with 10µg or 50µg 
N. brasiliensis L3 antigen or 1X PBS. Cells were incubated for 12 or 24 hours before harvesting the 
cells and extracting total protein. Western blotting was performed with antibodies specific for vimentin 
and N-cadherin with p38 used as the loading control. Densitometry readings were obtained using 
ImageJ to determine the changes in protein expression of vimentin and N-cadherin normalised to p38 
and expressed as a fold-change relative to control wells. This figure is representative of three 
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Figure 3.4: N. brasiliensis L3 antigen decreases Ca Ski cell migration. A and B. Migration was 
measured using a two-dimensional scratch motility assay. 1x105 cells were seeded per well in a 24-
well plate and allowed to reach confluency. Cells were treated with 0.1µg, 1µg or 10µg N. brasiliensis 
L3 antigen or 1X PBS and a sterile 2µl pipette tip was used to form a linear wound in the cell monolayer. 
Cells were imaged at 0, 4 and 8 hours post-wound formation with the total area migrated calculated 
relative to wound area at time 0 hours. C. Serum starved cells were seeded at a density of 1x105 cells 
per well into a 24-well transwell hanging-insert containing RPMI supplemented with 1% FBS and 10µg 
N. brasiliensis L3 antigen or 1X PBS. Each insert was then placed individually into a well containing 
RPMI supplemented with 10% FBS. Migrated cells, which had adhered to the lower surface of the 8µm 
membrane, were fixed with methanol and stained with crystal violet. 50% acetic acid was used to wash 
off the crystal violet stain and the absorbance of each well was read at a wavelength of 595nm. All the 
panels in this figure represent pooled data from three independent experiments each performed in 
triplicate. The data were analysed using GraphPad Prism 6.01 and a parametric unpaired t-test was 
performed *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. Error bars represent Standard Error of the 
Mean.  
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Figure 3.5: N. brasiliensis L3 antigen decreases C33-A cell migration. A and B. Migration was 
measured using a two-dimensional scratch motility assay. Cells were seeded at a density of 2x105
 
cells 
per well in a 24-well plate and allowed to reach confluency. Cells were treated with 0.1µg, 1µg or 10µg 
N. brasiliensis L3 antigen or 1X PBS and a sterile 2µl pipette tip was used to form a linear wound in the 
cell monolayer. Cells were imaged at 4 and 8 hours post-wound formation with the total area migrated 
calculated relative to wound area at time 0 hours. C. Serum starved cells were seeded at a density of 
1x105 cells per well into a 24-well transwell hanging-insert containing medium supplemented with 1% FBS 
and 10µg N. brasiliensis L3 antigen or 1X PBS. Each insert was then placed individually into a well 
containing medium supplemented with 10% FBS. Migrated cells, which had adhered to the lower surface 
of the 8µm membrane, were fixed with methanol and stained with crystal violet. 50% acetic acid was used 
to wash off the crystal violet stain and the absorbance of each well was read at a wavelength of 595nm. 
All the panels in this figure represent pooled data from three independent experiments each performed 
in triplicate. The data were analysed using GraphPad Prism 6.01 and a parametric unpaired t-test was 
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3.1.5 N. brasiliensis Infection Reduces the Expression of EMT Makers in the Mouse 
Female Genital Tract (FGT) 
The observations that N. brasiliensis L3 antigen reduces the expression of vimentin and N-
cadherin in both HPV positive and HPV negative cervical cancer cells begged the question 
whether live infection with N. brasiliensis would similarly affect these markers in non-
cancerous cervical tissue. Briefly to address this, mice were infected subcutaneously with 500 
L3 N. brasiliensis larvae and a week later the FGTs of infected and naïve mice were harvested 
and total protein extracted from them were subjected to western blotting with antibodies to 
vimentin and N-cadherin. The results revealed that, compared to the naïve mice, the FGTs of 
mice infected with N. brasiliensis had decreased expression of vimentin and N-cadherin 
(Figure 3.7A). Indeed, the densitometric analyses of the western blots show that the average 
expression of vimentin (Figure 3.7B) and N-cadherin (Figure 3.7C) in infected mice were 0.62 




Figure 3.6: N. brasiliensis L3 antigen decreases levels of EMT marker expression in C33-A cells. 
Cells were seeded at a density of 2x105 cells per well in a 6-well plate and treated with 10µg or 50µg 
N. brasiliensis L3 antigen or 1X PBS. Cells were incubated for 12 or 24 hours before harvesting the 
cells and extracting total protein. Western blotting was performed with antibodies specific for vimentin 
and N-cadherin with p38 used as the loading control. Densitometry readings were obtained using 
ImageJ to determine the changes in protein expression of vimentin and N-cadherin normalised to p38 
and expressed as a fold-change relative to control wells. This figure is representative of two 
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3.1.6 Cell-Surface Vimentin Expression and HPV16 Pseudovirion Internalisation is 
Diminished in N. brasiliensis L3 Antigen Treated HeLa Cells 
Gastrointestinal helminths have been implicated in increasing the susceptibility of cervical 
tissue to the cancer-causing virus HPV (162). Interestingly, cell-surface vimentin expression 
has been shown to act as a restriction factor on HeLa cells for HPV16 pseudovirions (163). 
Due to the decrease in total vimentin expression observed following exposure of HeLa cells 
to N. brasiliensis L3 antigen, the possibility was considered that the expression of cell-surface 
vimentin would be similarly reduced and lead to increased susceptibility to pseudovirion 
internalisation. To investigate this, HeLa cells were exposed to N. brasiliensis L3 antigen and 
cell-surface vimentin expression analysed by flow cytometry. The results showed that 50µg of 
N. brasiliensis L3 antigen also significantly reduced the expression of cell-surface vimentin 
(Figure 3.8). 
Figure 3.7: N. brasiliensis infection leads to reduced EMT marker expression in mouse female 
genital tracts (FGTs). A. FGTs were removed from four naïve and four N. brasiliensis infected mice, 
homogenised and total protein extracted and quantified. 20µg of protein was loaded onto an SDS-PAGE 
gel and western blotting was performed with antibodies specific for vimentin and N-cadherin with p38 
used as the loading control. This figure is representative of two independent experiments. Densitometry 
readings were obtained using ImageJ to determine the changes in protein expression of B. vimentin 
and C. N-cadherin normalised to p38. This figure shows pooled data from two independent experiments. 
The data were analysed using GraphPad Prism 6.01 and a parametric unpaired t-test was performed 


















































































































































To exclude the possibility that the N. brasiliensis L3 antigen used in the above experiments 
was contaminated with Lipopolysaccharide (LPS), which could have occurred during the 
harvesting process, and that the LPS was responsible for the effects seen, the Limulus 
Amoebocyte Lysate (LAL) assay was performed. The results showed that the N. brasiliensis 
L3 antigen contained low levels of endotoxin (2.80EU/ml) which is used as a proxy for LPS in 
this assay. However, when analysed by flow cytometry, the endotoxin (from 1µg of LPS) had 
no significant impact on cell-surface vimentin expression (Figure 3.8). Together this data 
confirm that the effect observed for N. brasiliensis L3 antigen on HeLa cell-surface vimentin 
was not due to contaminating LPS. 
The next experiment sought to determine whether the N. brasiliensis L3 antigen induced 
decrease in cell-surface vimentin expression correlated with an increase in pseudovirion 
internalisation. To this end, N. brasiliensis L3 antigen treated HeLa cells were incubated with 
fluorochrome-labelled HPV16 pseudovirions and the degree of internalisation of these  
Figure 3.8: N. brasiliensis L3 antigen decreases HeLa cell-surface vimentin expression. Cells 
were seeded at a density of 1x105 per well in a 24-well plate and treated with 10µg or 50µg N. 
brasiliensis L3 antigen, 1X PBS or 1µg LPS. A. Cells were incubated for 12 hours with N. brasiliensis 
L3 antigen, harvested in MACS buffer and analysed by flow cytometry. B. Graph shows pooled data 
from two independent experiments each performed in quadruplicate. The data were analysed using 
FlowJo Version 10 and GraphPad Prism 6.01 and a parametric unpaired t-test was performed *p<0.05 
**p<0.01 ***p<0.001 ****p<0.0001. Error bars represent Standard Error of the Mean. 
B 
50µg N. brasiliensis 
L3 Antigen 
Untreated 1µg LPS 
Cell-Surface Vimentin 


















































N . b ra s ilie n s is
























pseudovirions was determined by flow cytometry (Figure 3.9). Surprisingly, HPV16 
pseudovirion internalisation was significantly diminished in N. brasiliensis L3 antigen treated 
HeLa cells suggesting that the decrease in cell-surface vimentin expression did not 
significantly impact the degree of pseudovirion internalisation. 
Figure 3.9: N. brasiliensis L3 antigen decreases HPV16 pseudovirion internalisation by HeLa 
cells. Cells were seeded at a density of 1x105 cells per well in a 24-well plate and treated with 10µg 
or 50µg N. brasiliensis L3 antigen or 1X PBS. Cells were incubated for 12 hours with N. brasiliensis L3 
antigen before the addition of 400ng of HPV16 pseudovirions per well for 1 hour at 4°C and then 30 
minutes at 37°C. A. Flow cytometry analyses of cells subsequently harvested in MACS buffer. B. Graph 
shows pooled data from two independent experiments each performed in quadruplicate. The data were 
analysed using FlowJo Version 10 and GraphPad Prism 6.01 and a parametric unpaired t-test was 
performed *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. Error bars represent Standard Error of the 
Mean. 
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In summary, the results shown in section 3.1 provide compelling evidence that N. brasiliensis 
inhibits cervical cancer cell migration and HPV16 pseudovirion uptake, which is associated 
with a decrease in expression of EMT markers.  
3.2 Investigating the Effect of Heligmosomoides polygyrus Derived Antigens on 
Colorectal Cancer Behaviour in vitro 
The aim of this section was to determine the effect of antigens derived from the gastrointestinal 
nematode H. polygyrus on colorectal cancer cell behaviour using several in vitro assays. 
3.2.1 H. polygyrus Derived Antigens Significantly Decrease Colorectal Cancer Cell 
Proliferation with an Associated Increase in Expression of Cell Cycle Regulators  
To determine the effect of H. polygyrus derived antigens on colorectal cancer cells, CT26.WT 
cells were exposed to 10µg HES or 10µg H. polygyrus antigen and cell proliferation was 
monitored by counting cells over a 3-day period using a haemocytometer. Figure 3.10A shows 
that both H. polygyrus derived antigens significantly decreased cell proliferation at 3 days post-
treatment.  
As in section 3.1, the LAL assay was performed to exclude the possibility that H. polygyrus 
derived antigens were contaminated with LPS. The results showed that HES and H. polygyrus 
antigen contained low endotoxin levels of 0.7EU/ml and 2.8EU/ml respectively.  
It was speculated that H. polygyrus derived antigens may be supressing CT26.WT cell 
proliferation by activating cell cycle regulator proteins. To investigate this, protein levels of the 
tumour suppressor p53 and its downstream target gene p21 were determined by western 
blotting using protein from CT26.WT cells treated as described above. The results showed 
that, compared to the untreated control cells, the expression of p53 and p21 were considerably 
higher following treatment with these antigens (Figure 3.10B).  
To determine whether this effect was H. polygyrus specific, CT26.WT cells were exposed to 
SEA, egg antigen from Schistosoma mansoni, a blood fluke associated with colorectal cancer 
development (164, 165). Surprisingly, SEA had no effect on CT26.WT cell proliferation (Figure 
3.10C), suggesting that the inhibitory effect of H. polygyrus derived antigens on CT26.WT cell 
proliferation is specific to this nematode. 
To validate the findings that H. polygyrus derived antigens inhibit CT26.WT cell proliferation 
the cells were treated as described earlier and the Methylthiazol Tetrazolium (MTT) and 














Figure 3.10: H. polygyrus derived antigens decrease CT26.WT cell proliferation and increase 
cell cycle regulator protein expression. A. 5x104 cells were seeded per well in a 24-well plate and 
treated with 10µg HES, 10µg H. polygyrus antigen or 1X PBS. Growth curve analyses were performed 
over a 3-day period by harvesting trypsinised cells and counting the cells using a haemocytometer. B. 
2x105
 
cells were seeded per well in a 6-well plate and treated with 10µg HES, 10µg H. polygyrus 
antigen or 1X PBS for 12 or 18 hours before harvesting the cells and extracting the total protein. 
Western blotting was performed with antibodies specific for p53 and p21 with p38 used as the loading 
control. This result is representative of three independent experiments. Densitometry readings were 
obtained using ImageJ to determine the changes in protein expression of p53 and p21 normalised to 
p38 and expressed as a fold-change relative to control wells. C. 5x104
 
cells were seeded per well in a 
24-well plate and treated with 0.1µg, 1µg or 10µg SEA or 1X PBS. Growth curve analyses were 
performed over a 3-day period by harvesting trypsinised cells and counting the cells using a 
haemocytometer. This figure shows pooled data from four (A) and two (C) independent experiments 
each performed in triplicate. The data were analysed using GraphPad Prism 6.01 and a parametric 
unpaired t-test was performed *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. Error bars represent 
Standard Error of the Mean. 
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Figure 3.11: HES, but not H. polygyrus antigen, decreases CT26.WT cell viability and BrdU 
incorporation. A. 4x103 cells were seeded per well in a 96-well plate and treated with 10µg HES, 
10µg H. polygyrus antigen or 1X PBS for 48 hours. MTT was added to each well for 4 hours followed 
by the addition of the solubilizer and 24 hours later the absorbance of each well was read at a 
wavelength of 595nm. B. 2x105
 
cells were seeded in a 35mm dish and treated with 10µg HES, 10µg 
H. polygyrus antigen or 1X PBS. 8 hours before immuno-processing 10µM BrdU was added to each 
dish and the relevant cells co-stained with DAPI. An Axiovert Fluorescent microscope (Zeiss, 
Germany) was used to visualise and image 15 fields of view per treatment condition. C. To quantify 
the images, the presence of a green nuclear stain, compared to a blue DAPI only nuclear stain, was 
concluded to be BrdU positive (white arrows). This figure shows pooled data from three (A) and two 
(B and C) independent experiments each performed in triplicate. The data were analysed using 
GraphPad Prism 6.01 and a parametric unpaired t-test was performed *p<0.05 **p<0.01 ***p<0.001 
****p<0.0001. Error bars represent Standard Error of the Mean. 
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Results from the MTT assay (Figure 3.11A) and BrdU incorporation (Figure 3.11B and 
Figure 3.11C) assays showed that HES treatment indeed resulted in a significant reduction 
in CT26.WT cell viability/proliferation. However, no significant effect was observed for H. 
polygyrus antigen treatment.  
The CT26.WT cell line is a murine colorectal cancer cell line and it was therefore, of interest 
to determine whether the H. polygyrus derived antigens would similarly inhibit the proliferation 
of a human colorectal cancer cell line, HCT116. As observed in CT26.WT cells, growth curve 
analyses showed that the proliferation of HCT116 cells was significantly decreased following 
treatment with both HES and H. polygyrus antigen (Figure 3.12A). Furthermore, the 
expression of p53 and p21 was notably elevated in treated compared to untreated cells 
(Figure 3.12B). Consistent with the MTT results obtained for the murine CT26.WT colorectal 
cancer cells, HES caused a trend towards lowered cell viability of the human HCT116 cells 
(Figure 3.12C). In contrast to the MTT assay results obtained for the CT26.WT cells, however, 
H. polygyrus antigen significantly decreased human HCT116 cell viability (Figure 3.12C). 
3.2.2 H. polygyrus Derived Antigens Significantly Alter Colorectal Cancer Cell Migration 
Having established that antigen derived from H. polygyrus significantly decreased both 
CT26.WT and HCT116 cell proliferation, whether these antigens would alter cell migration was 
of interest. To this end, CT26.WT and HCT116 cells were exposed to HES and H. polygyrus 
antigen and their migratory ability measured using the transwell migration assay. Interestingly, 
the results obtained showed that while HES and H. polygyrus antigen significantly increased 
CT26.WT cell migration (Figure 3.13A), they significantly reduced the migration of HCT116 
cells (Figure 3.13B). These results indicated that HES and H. polygyrus antigen impacted the 
migratory ability of mouse and human colorectal cancer cells differently. 
In an attempt to explain the molecular mechanism by which HES and H. polygyrus antigen 
affected colorectal cancer cell migration, the levels of β-catenin were determined using 
western blotting. The rationale for this was that β-catenin levels have been positively 
associated with colitis-associated colorectal cancer (CAC) tumourigenesis and, in particular, 
migration (100, 166-169). β-catenin levels increased in the mouse CT26.WT cells treated with 
H. polygyrus derived antigens which correlated well with their pro-migratory effect on these 
cells (Figure 3.13C). On the other hand, H. polygyrus derived antigens decreased β-catenin 
levels in human HCT116 cells which was consistent with their inhibitory effect on the migration 

























performed once and that it would need to be repeated before any conclusive deductions are 
made. 
 
Figure 3.12: H. polygyrus derived antigens decrease HCT116 cell proliferation and increase cell 
cycle regulator protein expression. A. 5x104 cells were seeded per well in a 24-well plate and treated 
with 10µg HES, 10µg H. polygyrus antigen or 1X PBS. Growth curve analyses were performed over a 
3-day period by harvesting trypsinised cells and counting the cells using a haemocytometer. B. 2x105 
cells were seeded per well in a 6-well plate and treated with 10µg HES, 10µg H. polygyrus antigen or 
1X PBS. Cells were incubated for 24 or 30 hours before harvesting the cells and extracting the total 
protein. Western blotting was performed with antibodies specific for p53 and p21 with p38 used as the 
loading control. This result is representative of two independent experiments. Densitometry readings 
were obtained using ImageJ to determine the changes in protein expression of p53 and p21 normalised 
to p38 and expressed as a fold-change relative to control wells. C. 4x103 cells were seeded per well in 
a 96-well plate and treated with 10µg HES, 10µg H. polygyrus antigen or 1X PBS for 48 hours. MTT 
was added to each well for 4 hours followed by the addition of the solubilizer and 24 hours later the 
absorbance of each well was read at a wavelength of 595nm. A and C. Show pooled data from three 
independent experiments each performed in triplicate. The data were analysed using GraphPad Prism 
6.01 and t-test was performed *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. Error bars represent 
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Figure 3.13: H. polygyrus antigens alter colorectal cancer cell migration in a species-specific 
manner. Serum starved CT26.WT (A) and HCT116 (B) cells were seeded at a density of 1x105 cells 
per well of a 24-well transwell hanging-insert containing the relevant medium supplemented with 1% 
FBS and 10µg HES, 10µg H. polygyrus antigen or 1X PBS. Each insert was then placed individually 
into a well containing medium supplemented with 10% FBS. Migrated cells which had adhered to the 
lower surface of the 8µm membrane were fixed with methanol and stained with crystal violet. 50% 
acetic acid was used to wash off the crystal violet stain and the absorbance of each well was read at 
a wavelength of 595nm. C and D. Cells were seeded at a density of 2x105 cells per well in a 6-well 
plate and treated with 10µg HES or 10µg H. polygyrus antigen or 1X PBS. Cells were incubated for 
12 or 18 hours (C) or 24 or 30 hours (D) before harvesting the cells and extracting the total protein. 
Western blotting was performed with antibodies specific for β-catenin with p38 used as the loading 
control. Densitometry readings were obtained using ImageJ to determine the changes in protein 
expression of β-catenin normalised to p38 and expressed as a fold-change relative to control wells. 
Broken lines in western blots shown in this figure indicate where lanes not relevant were removed. A 
and B. represent pooled data from three independent experiments each performed in triplicate. The 
data were analysed using GraphPad Prism 6.01 and a t-test was performed *p<0.05 **p<0.01 
***p<0.001 ****p<0.0001. Error bars represent Standard Error of the Mean.  






















































































































































































































































































3.2.3 HES Significantly Increases Mouse CT26.WT Colorectal Cancer Tumour Growth 
The H. polygyrus derived antigens significantly reduced the proliferation of CT26.WT cells in 
vitro which suggested that they may have some therapeutic benefits for colorectal cancer. 
Therefore, their effect on the tumour forming ability of these cells in vivo was determined. 
Briefly, CT26.WT cells treated with either HES or H. polygyrus antigen were injected 
subcutaneously into the flanks of BALB/c mice and the tumours measured every second day 
over a period of 14 days. While the results show that there was an increase in tumour growth 
for all treatments tested, tumours derived from HES treated CT26.WT cells displayed 
drastically accelerated growth (Figure 3.14A) and were significantly larger upon resection 
(Figure 3.14B). There was, therefore a discrepancy between the proliferative ability of 
CT26.WT cells exposed to H. polygyrus derived antigens in vitro and in vivo.  
To further investigate the tumour promoting activity of HES on mouse colorectal cancer cells 
in vivo, the inguinal draining lymph nodes (dLN) and non-draining lymph nodes (ndLN) were 
removed from the tumour bearing mice described above and the immune cell populations 
present in these structures were explored by flow cytometry. Although there were no 
differences in the proportion of CD4+ T cells present in the dLN or ndLN between treatment 
groups (Figure 3.15A and Figure 3.15E), the dLNs from mice bearing tumours derived from 
HES treated CT26.WT cells contained significantly higher total CD4+ T cell numbers (Figure 
3.15B). A similar trend was observed for CD8+ T cells (Figures 3.15C. 3.15D and 3.15F). 
HES is well documented to expand the regulatory Foxp3+ T cell population, responsible for 
suppressing the immune response, in mice and humans (16, 33). It was, therefore important 
to determine whether this immune-regulatory T cell population was expanded in the dLN of 
mice bearing tumours derived from HES treated CT26.WT cells. Flow cytometric analysis 
showed that indeed, mice bearing these tumours had significantly higher proportions and 
numbers of Foxp3+ T cells present in the dLN (Figure 3.16). Foxp3+ T cells have been 
implicated in dampening anti-tumour immunity, therefore it is possible that the accumulation 
of Foxp3+ T cells in the dLN could have contributed towards the increased growth of tumours 
derived from HES treated CT26.WT cells (170-172).  
To determine whether the immune response observed above in the lymph nodes of mice was 
also relevant to the tumours themselves, the experiments described above were repeated for 
















Mice bearing tumours derived from HES treated CT26.WT cells had lower proportions and 
total CD4+ T cell numbers within the tumour, while the opposite was observed for tumours 
derived from H. polygyrus antigen treated CT26.WT cells (Figures 3.17A, 3.17B and 3.17E). 
Furthermore, although no differences were observed in the proportion of Foxp3+ T cells 
present in the tumours between treatment groups (Figure 3.17C and Figure 3.17F), tumours 
derived from HES treated CT26.WT cells had a significantly higher number of Foxp3+ T cells 
(Figure 3.17D). This further implicates HES as an accelerant of CT26.WT tumour growth due 
to Foxp3+ Treg population expansion.  
Additionally, tumours derived from treated CT26.WT cells had lower proportions of CD11b+ 
cells (Figure 3.18A and Figure 318C) but a trend towards a higher number of total CD11b+ 
cells (Figure 3.18B). Notably, these tumours also had higher proportions of neutrophils 
(Figure 3.19A and Figure 3.19C) and a significantly higher total number of neutrophils 
(Figure 3.19B). 
Section 3.2 reveals that H. polygyrus derived antigens can alter colorectal cancer cell 
migration and proliferation which is associated with changes in cell cycle regulator protein 
expression. Furthermore, these antigens have a notable impact on colorectal cancer tumour 




Figure 3.14: HES significantly accelerates CT26.WT tumour growth. 8-week-old BALB/c mice were 
injected subcutaneously with 5x105 CT26.WT cells treated with either 10µg HES, 10µg H. polygyrus 
antigen or 1X PBS. A. Tumour height and width were measured using callipers and the tumour volume 
calculated using the equation V=0.5(HxW2). * Untreated vs. HES, # HES vs. H. polygyrus antigen. B. 
Mice were sacrificed 14 days later, and the tumours resected and weighed. The data were analysed 
using GraphPad Prism 6.01 and an unpaired t-test was performed *p<0.05 **p<0.01 ***p<0.001 
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Figure 3.15: HES elevates total CD4+ and CD8+ T cell numbers in the draining lymph node (dLN) 
of mice bearing tumours derived from HES treated CT26.WT cells. 8-week-old BALB/c mice were 
injected subcutaneously with 5x105 CT26.WT cells treated with either 10µg HES, 10µg H. polygyrus 
antigen or 1X PBS. Mice were sacrificed 14 days later and the draining lymph nodes (dLN) and non-
draining lymph nodes (ndLN) removed. Cells were stained as described in the Materials and Methods 
section of this thesis and analysed by flow cytometry on the ACEA Novocyte. A. Percentage and B. 
Total CD4+ T cells. C. Percentage and D. Total CD8+ T cells. Representative dot plots showing the E. 
CD4+ and F. CD8+ T cell populations in the dLN for each treatment analysed using FlowJo Version 10. 
Analysis was performed using GraphPad Prism 6.01 and a parametric unpaired t-test was performed 
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Figure 3.16: HES significantly increases the proportion and number of regulatory Foxp3+ T cells 
in the draining lymph node (dLN) of tumours derived from treated CT26.WT cells. 8-week-old 
BALB/c mice were injected subcutaneously with 5x105 CT26.WT cells treated with either 10µg HES, 
10µg H. polygyrus antigen or 1X PBS. Mice were sacrificed 14 days later and the draining lymph nodes 
(dLN) and non-draining lymph nodes (ndLN) removed. Cells were stained as described in the Materials 
and Methods section of this thesis and analysed by flow cytometry on the ACEA Novocyte. A. 
Percentage and B. Total CD3+ CD4+ Foxp3+ T cells. Representative dot plots showing the C. Foxp3+ 
population in the dLN for each treatment analysed using FlowJo Version 10. Analysis was performed 
using GraphPad Prism 6.01 and a parametric unpaired t-test was performed *p<0.05 **p<0.01 



















Figure 3.17: HES significantly increases the number of regulatory Foxp3+ T cells in CT26.WT 
tumours. 8-week-old BALB/c mice were injected subcutaneously with 5x105 CT26.WT cells treated with 
either 10µg HES, 10µg H. polygyrus antigen or 1X PBS. Mice were sacrificed 14 days later, and the 
tumours removed, stained as described in the Materials and Methods section of this thesis and analysed 
flow cytometry on the ACEA Novocyte. A. Percentage and B. Total CD4+ T cells. C. Percentage and D. 
Total CD3+ CD4+ Foxp3+ T cells. Representative dot plots showing the E. CD3+ CD4+ and F. CD3+ 
CD4+ Foxp3+ populations for each treatment analysed using FlowJo Version 10. Analysis was 
performed using GraphPad Prism 6.01 and a parametric unpaired t-test was performed *p<0.05 
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Figure 3.18: HES significantly decreases the proportion of CD11b+ cells in the tumour. 8-
week-old BALB/c mice were injected subcutaneously with 5x105 CT26.WT cells treated with either 
10µg HES, 10µg H. polygyrus antigen or 1X PBS. Mice were sacrificed 14 days later, and the 
tumours removed, stained as described in the Materials and Methods section of this thesis and 
analysed flow cytometry on the ACEA Novocyte. A. Percentage and B. Total CD11b+ cells. 
Representative dot plots showing the C. CD11b+ population for each treatment analysed using 
FlowJo Version 10. Analysis was performed using GraphPad Prism 6.01 and a parametric unpaired 
t-test was performed *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. Error bars represent Standard 













































Figure 3.19: H. polygyrus derived antigens significantly increase the number neutrophils in 
CT26.WT tumours. 8-week-old BALB/c mice were injected subcutaneously with 5x105 CT26.WT cells 
treated with either 10µg HES, 10µg H. polygyrus antigen or 1X PBS. Mice were sacrificed 14 days 
later, and the tumours removed, stained as described in the Materials and Methods section of this 
thesis and analysed flow cytometry on the ACEA Novocyte. A. Percentage and B. Total neutrophils. 
Representative dot plots showing the C. Neutrophil population for each treatment analysed using 
FlowJo Version 10. Analysis was performed using GraphPad Prism 6.01 and a parametric unpaired t-
test was performed *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. Error bars represent Standard Error 
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3.3 Investigating the Role of HES in a Murine Model of Colitis-Associated Colorectal 
Cancer (CAC) 
Having determined that HES had significant effects on in vitro colorectal cancer cell behaviour 
and in vivo colorectal cancer tumour growth, whether it would alter the development of 
colorectal cancer was uncertain. To investigate this, a murine model of CAC was utilised. It is 
important to note that infection with H. polygyrus in the early stages of CAC has been shown 
to exacerbate tumour development, however whether HES is able to effect CAC has yet to be 
determined (103). 
3.3.1 HES Treatment Worsens Pathology in a Murine Model of CAC 
To explore whether HES can affect the development of CAC, mice were injected 
intraperitoneally with the carcinogen azoxymethane (AOM) and exposed to an inflammatory 
agent Dextran Sulphate Sodium (DSS) in their drinking water for one week. Over the course 
of 15 days, mice were injected peritoneally with either HES or a PBS control and the weight, 
distress scores, colon lengths and weight and total cell count of the spleen determined. 
The results showed that mice treated with HES/AOM/DSS had a worse pathology compared 
to that of naïve or AOM/DSS treated mice. This was evident by increased weight loss (Figure 
3.20A) and shortened colons (Figure 3.20B). No significant difference was seen between 
spleen weights (Figure 3.22C) and spleen total cell counts (Figure 3.20D) for the various 
conditions tested. However, compared to naïve mice the HES/AOM/DSS treated and 
AOM/DSS groups of mice, had a trend towards larger spleens with higher spleen total cell 
counts (Figure 3.20C and Figure 3.20D).  
To determine whether HES/AOM/DSS altered the structure and integrity of the colon, 5µm 
thick colon sections were stained with Haematoxylin and Eosin (H&E) and Periodic Acid-Schiff 
(PAS). While Haematoxylin binds negatively charged substances such as DNA and stains 
nuclei dark blue, Eosin binds positively charged substances such as certain amino acids and 
stains the cytoplasm pink/red. PAS on the other hand is a specialised stain that binds and 
stains polysaccharides and mucosubstances such as mucins produced by goblet cells. Colon 
sections isolated from HES/AOM/DSS and AOM/DSS treated mice exhibited reduced goblet 
cells (light PAS staining), large submucosal spaces (black arrows), which is illustrative of 
oedema, lymphocyte infiltration (yellow arrows) and advanced epithelial injury (white arrows) 
(Figure 3.21A). Although no significant differences were observed between HES/AOM/DSS 
and AOM/DSS treatment groups, HES/AOM/DSS mice did tend to have higher pathology 






















To determine the impact of the HES/AOM/DSS and AOM/DSS treatments on the immune cell 
populations, the spleens of the naive and treated mice were removed and analysed by flow 
cytometry. The results showed that spleens from the HES/AOM/DSS treated mice had a 
significantly larger proportion of CD11b+ cells compared to that of naïve mice and a trend 
towards higher than that of AOM/DSS treated mice (Figure 3.22A and Figure 3.22C). Both 
the groups of HES/AOM/DSS and AOM/DSS treated mice had higher numbers of total 
CD11b+ cells present in the spleen compared to naïve mice, however this was only significant 
for AOM/DSS treated mice (Figure 3.22B). Furthermore, compared to naïve mice, AOM/DSS 
treated mice had significantly higher proportions of eosinophils and neutrophils (Figures 
3.22D, 3.22F, 3.22G and 3.22I) and they had a trend towards higher total cell counts of these 
cells (Figure 3.22E and Figure 3.22H). Unfortunately, due to the variations in results obtained 
for mice treated with HES/AOM/DSS, the results were not significant and future studies would 
have to increase the number of mice in treatment groups. 
Figure 3.20: HES worsens pathology in a murine model of colitis-associated colorectal cancer 
(CAC). A. Percentage weight loss over 15 days. * HES/AOM/DSS compared to Naïve. B. Colon length 
(mm) measured from the end of the cecum to the rectum. C. Spleen weight (g) and D. Spleen total cell 
count. The data were analysed using GraphPad Prism 6.01 and a parametric unpaired t-test was 
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* Figure 3.21: HES worsens pathology in a murine model of colitis-
associated colorectal cancer (CAC). A. PAS and H&E staining on 5µm 
thick colon sections. Black arrows indicate oedema, yellow arrows indicate 
cell infiltration and white arrows indicate epithelial injury. B. Histology 
scores based on goblet cell abundance, epithelial injury, cell infiltration and 
oedema. Each criterion was scored from 0 to 3. C. Graph showing 
cumulative pathology scores per treatment group. The data were analysed 
using GraphPad Prism 6.01 and a parametric unpaired t-test was 
performed *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. Error bars 







In the case of the adaptive immune system, compared to naïve mice, HES/AOM/DSS treated 
mice had comparable CD4+ T cell proportions (Figures 3.23A and 3.23E) and a trend towards 
higher total CD4+ T cell counts (Figure 3.23B). Similar results were obtained for the 
AOM/DSS treated mice (Figure 3.23A, 3.23B and 3.23E) compared to naïve mice. Lastly, 
compared to naïve mice, HES/AOM/DSS and AOM/DSS treatment groups had similar CD4- 
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Figure 3.23: HES treatment decreases the total CD4+ and CD4- populations in a murine model 
of Colitis-Associated Colorectal Cancer (CAC). Splenocytes were seeded at a density of 1x10
5
 cells 
per well in a 96-well round-bottom plate, labelled and fixed appropriately and analysed by flow 
cytometry. The A. percentage and B. Total CD4+ cells, C. percentage and D. Total CD4- present in 
each sample. E. Representative dot plots showing the CD4+ and CD4- populations for each treatment 
analysed using FlowJo Version 10. Analysis was performed using GraphPad Prism 6.01 and a 
parametric unpaired t-test was performed *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. Error bars 
represent Standard Error of the Mean.  
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3.3.2 Increased morbidity and mortality induced by HES treatment is TFG-β dependent 
HES contains a structurally distinct TGF-β mimic, which can signal via the canonical TGF-β 
receptor pathway and be antagonised by TGF-β receptor inhibitors (16, 33). It was speculated 
that this mimic could be the cause of the increased morbidity experienced by HES/AOM/DSS 
mice compared to AOM/DSS and naïve mice. To explore this possibility, the above 
experiments were repeated in the presence or absence of the TGF-β inhibitor, SB-431542 and 
weight, distress scores, colon lengths and weight and total cell count of the spleen were 
determined. 
Mice treated with HES/AOM/DSS only experienced the most weight loss (Figure 3.24A and 
3.24B) and mortality (Figure 3.24C) and, in the presence of SB-431542 this group of mice 
had zero mortality and weight loss comparable to the AOM/DSS only treated mice. 
HES/AOM/DSS only treated mice also had the highest distress scores out of the four groups 
(Figure 3.24D). While there was no difference in colon lengths between that of 
HES/AOM/DSS and HES/AOM/DSS/SB-431542 treated mice (Figure 3.24E), the spleen 
weights (Figure 3.24F) and spleen total cell counts (Figure 3.24G) were higher in the 
HES/AOM/DSS treated group. 
To further understand the impact of the TGF-β mimic in the HES/AOM/DSS treated mice, the 
spleens of the naive and treated mice were removed and analysed by flow cytometry. The 
results showed that the spleen of HES/AOM/DSS treated mice had a significantly larger 
proportion (Figure 3.25A and Figure 3.25B) and total cell number (Figure 3.25C) of CD11b+ 
cells compared to the other treatment groups. Importantly, HES/AOM/DSS/SB-431542 treated 
mice had CD11b+ proportions (Figure 3.25A and Figure 3.25B) and total CD11b+ cell counts 
(Figure 3.25C) comparable to that of naïve and AOM/DSS treated mice suggesting that the 
increase in the CD11b+ population, in HES/AOM/DSS treated mice, is TGF-β dependent. Due 
to an unexpected problem with the staining of the eosinophil and neutrophil populations an 







Figure 3.22: HES treatment increases the CD11b+, eosinophil and neutrophil populations in a 
murine model of colitis-associated colorectal cancer (CAC). Splenocytes were seeded at a density 
of 1x105 cells per well in a 96-well round-bottom plate, labelled and fixed appropriately and analysed by 
flow cytometry. The A. percentage and B. Total CD11b+ cells, D. percentage and E. Total eosinophils, 
G. percentage and H. Total neutrophils present in each sample. Representative dot plots showing the 
C. CD11b+, F. Eosinophil and I. Neutrophil populations for each treatment analysed using FlowJo 
Version 10. Analysis was performed using GraphPad Prism 6.01 and a parametric unpaired t-test was 
performed *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. Error bars represent Standard Error of the Mean.  
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However, the CD4+ and CD4- T cell proportions and total cell counts were not TGF-β 
dependent and were either lower (CD4+) or higher (CD4-) in all three treatment groups 
compared to that of naïve mice (Figure 3.26).  
It is important to note that the experiments in sections 3.3.1 and 3.3.2 were only performed 
once and would need to be repeated before any conclusive deductions can be made. To 
reduce inter-group variations, more mice should be included in each group. 
The in vivo results in this final section suggest that in a model of CAC, HES significantly 
exacerbates disease in a manner at least partially dependent on TGF-β and the accumulation 







Figure 3.24: Increased morbidity and mortality induced by HES treatment is TFG-β dependent. 
A. Percentage weight loss over 15 days. B. Percentage weight loss from Day 5 – start of DSS. C. 
Survival curve over 15 days. D. Daily individual distress scores. E. Colon length (mm) measured from 
the end of the cecum to the rectum. F. Representative colons from each group G. Spleen weight (g). H. 
Spleen total cell counts. The data were analysed using GraphPad Prism 6.01 and a two-way ANOVA 
with multiple comparisons (A and B), a parametric unpaired t-test (D) or a one-way ANOVA with multiple 
comparisons (E-G) was performed *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. Error bars represent 
Standard Error of the Mean. 
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Figure 3.25: Increased CD11b+ proportions and total cell counts, induced by HES treatment, is 
TFG-β dependent. Splenocytes were seeded at a density of 1x105 cells per well in a 96-well round-
bottom plate and labelled and fixed appropriately and A. Representative dot plots showing the CD11b+ 
populations for each treatment analysed using FlowJo Version 10. The B. Percentage and C. Total 
CD11b+ cells present in each sample. Analysis was performed using GraphPad 6.01 and a parametric 
one-way ANOVA with multiple comparisons was performed *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. 
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Figure 3.26: The effect of HES treatment on the CD4+ and CD4- T cell population is TFG-β 
independent. Splenocytes were seeded at a density of 1x105
 
cells per well in a 96-well round-bottom 
plate and labelled and fixed appropriately and A. Representative dot plots showing the eosinophils 
population for each treatment analysed using FlowJo Version 10. The B. Percentage and C. Total 
CD4+ and D. Percentage and E. Total CD4- T cells present in each sample. Analysis was performed 
using GraphPad 6.01 and a parametric one-way ANOVA with multiple comparisons was performed 























Although specific helminths are irrefutable causes of cancer, certain other helminths have 
been shown to modulate the host immune response by promoting immune suppression (5-7, 
67, 75, 107, 173, 174). However, the exact mechanisms that these helminths employ to modify 
the host immune system and promote immune regulation is largely unclear (105). For this 
reason, the potential for the use of these parasites in impeding cancer progression is worth 
thorough investigation. This study, therefore aimed to determine the effect that certain 
helminths have on cervical and colorectal cancer cell behaviour 
4.1 The Role of N. brasiliensis in Cervical Cancer Development and Progression 
Epidemiological studies have revealed a positive correlation between infection with soil-
transmitted helminths (STH) and susceptibility to the oncogenic virus HPV (80). However, 
whether exposure to STHs can directly influence cervical cancer cell growth and migration is 
not known. Consequently, this study utilised N. brasiliensis, a rodent hookworm commonly 
used to model infection with the human hookworms Necator americanus and Ancylostoma 
duodenale, to investigate the effect of STH exposure on HPV positive and negative cervical 
cancer behaviour in vitro (148).  
While N. brasiliensis L3 antigen had no significant effect on HPV18 positive HeLa cell 
proliferation, high concentrations of the antigen significantly decreased cell migration in two-
dimensional scratch motility and transwell migration assays. Even though the clinical 
relevance of the 1.36 fold decrease in HeLa cell migration observed using the transwell 
migration assay requires further investigation, this result is comparable to what has previously 
been defined as a significant decrease in HeLa cell migration following drug treatment (175). 
Although antigen derived from C. sinensis and S. haematobium has been documented to 
cause an increase in the migration of cholangiocarcinoma (CCA) and normal epithelial cells 
respectively, this is the first time a decrease in cervical cancer cell migration following 
treatment with helminth derived proteins has been observed (176-179). Notably, the inhibitory 
effect on migration appeared to be hookworm specific as HeLa cells exposed to antigen 
derived from H. polygyrus, a solely gastrointestinal nematode, had no significant changes in 
cell migration. 
The reduction in HeLa cell migration was found to be associated with the lowered expression 
of EMT markers, N-cadherin and vimentin. N-cadherin, a transmembrane cell adhesion 
molecule (NCBI Gene ID: 1000), and vimentin, an intermediate filament protein (NCBI Gene 
ID: 7431), are both expressed by mesenchymal cells and are used as markers of cells which 
are undergoing, or have undergone, EMT. Indeed, both N-cadherin and vimentin have been 
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associated with the transition of epithelial cells to a more invasive and metastatic 
mesenchymal cell type, which is associated with a poor outcome (180-182). Importantly, in 
accordance with the presented data, previous studies have also shown that helminths can 
impact the EMT process. S. haematobium-induced sarcomas expressed raised levels of 
vimentin and, when co-administered with a chemical carcinogen into the murine bladder, S. 
haematobium eggs reduced E-cadherin and elevated vimentin expression in urothelial cells 
(138, 139). Furthermore, infection with H. polygyrus or T. spiralis has been reported to reduce 
the expression of E-cadherin and Occludin in the colon respectively (140, 141). Likewise, in 
humans, infection with T. trichiura and S. mansoni increased the expression of plasma 
fibronectin and cellular vimentin respectively (142, 143). The previously described studies all 
reveal an increased potential for metastasis following helminth exposure, however the results 
from the current study suggest that N. brasiliensis L3 antigen could act as a late-stage cervical 
cancer treatment by decreasing the proportion of cancer cells progressing to metastasis.  
The decline in HeLa cell migration following N. brasiliensis L3 antigen treatment was validated 
in the HPV16 positive cell line, Ca Ski, using two-dimensional scratch motility assays only. 
Despite numerous attempts, western blotting results which investigated the changes in Ca Ski 
EMT expression were inconsistent. This was not due to technical error but rather that the 
results obtained varied between experiments. This may be due to Ca Ski cells having a 
different level of sensitivity to N. brasiliensis L3 antigen compared to HeLa cells, leading to 
unreliable outcomes. Furthermore, while both the HeLa and Ca Ski cell lines are derived from 
cancerous epithelial cervical tissue, HeLa cells (ATCC CCL-2) were harvested directly from 
the cervix and Ca Ski cells (ATCC CRL-1550) were isolated from a metastatic site in the small 
intestine. Importantly, these cells lines have been reported to respond differently to treatment, 
therefore it is possible that the vastly different environments from which each cell line 
originates affects its overall behaviour to external signals and treatments (183).  
The reduction in N. brasiliensis L3 antigen treated HeLa cell migration and EMT expression 
was, however confirmed in a HPV negative cell line, C33-A (ATCC HTB-31), which was also 
harvested directly from the cervix. Interestingly, this cell line appeared to be the most sensitive 
to N. brasiliensis L3 antigen as even low concentrations of the antigen used in the two-
dimensional scratch motility assay significantly lowered cell migration. This cell line has been 
documented to be more sensitive to chemotherapeutic drugs compared to HeLa and Ca Ski 
cells, however whether this has to do with its HPV status remains to be determined (184, 185). 
Although the effect of N. brasiliensis L3 antigen on cervical cancer cell migration is important 
to understand, it would also be beneficial to determine whether this antigen can alter the 
invasive potential of cervical cancer. One possibility to achieve this involves the use of a 
matrigel which can be added to the apical surface of the transwell hanging-insert membrane, 
91 
 
and the percentage of treated cells which enter the matrigel can then be compared to that of 
untreated cells (175). 
Once the in vitro effect of N. brasiliensis L3 antigen treatment on cervical cancer cell migration 
and EMT expression had been determined, the in vivo effect of live infection on non-cancerous 
murine FGT tissue was investigated. The results revealed that N. brasiliensis infected mice 
displayed reduced vimentin and N-cadherin expression in the FGT compared to that of naïve 
mice. This is significant because N. brasiliensis does not enter the genital tissue of the host 
during its lifecycle, therefore the observed effect on EMT marker expression in the FGT must 
be systemic and independent of direct contact with the parasite. This is not uncommon as 
several gastrointestinal helminths, including N. brasiliensis, are able to exert non-enteric 
effects on the immune system (186). Following infection with N. brasiliensis, a robust 
expansion of IL-13-expressing innate cells is observed (187). These cells are abundant in the 
non-enteric tissue, including the Mesenteric Lymph Node (MLN), spleen and liver, and play a 
critical role in the Th2 immune response and worm expulsion. It is therefore reasonable to 
hypothesise that these IL-13-expressing cells may be systemically altering the expression of 
genital tract EMT markers in a way that impairs cervical cancer progression.  
Cell-surface vimentin acts as a cancer-specific EMT marker and has been implicated as a 
restriction factor for HPV16 pseudovirion entry (137, 163, 188-191). The decrease in cell-
surface vimentin expression by N. brasiliensis L3 antigen treated HeLa cells was, therefore 
expected to result in an increase in HPV16 pseudovirion internalisation. This was, however, 
not the case and instead a significant decrease in pseudovirion internalisation was seen. It is, 
however, important to note that HPV has multiple receptors and restriction factors and 
therefore changes in the expression of only one of these proteins may not necessarily have 
an overall effect on viral internalization (192). It would be beneficial to clarify the effect of 
changes in cell-surface vimentin expression on HPV infectivity. To achieve this, pseudovirions 
expressing the luciferase reporter enzyme could be utilised. This would be valuable because 
only when the luciferase gene has been fully incorporated into the host’s genome would 
luciferase be expressed, and a light signal detected. Differences in the detectable light signal 
between control and N. brasiliensis L3 antigen treated HeLa cells (expressing lowered cell-
surface vimentin) could then be used as a measure of successful HPV infection. 
Hookworm exposure has never been implicated in reducing cervical cancer cell migration 
through the modulation of cell-surface EMT markers. A previous study showed that HeLa cells 
exposed to the ES products derived from the sheep nematodes Haemonchus contortus and 
Ostertagia circumcincta had increased vacuolation and loss of cell contact (193). Interestingly, 
both products were also reported to increase the permeability of CACO-2 (human epithelial 
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colorectal adenocarcinoma) cell monolayers, through the re-arrangement of tight junction 
proteins ZO-1 and Occludin (194). It is possible that N. brasiliensis L3 antigen alters the 
migration of cervical cancer cells through the modulation of cell-surface markers common to 
the formation of tight junctions and the EMT process. However, the effect of N. brasiliensis on 
the expression of tight junction proteins would need to be determined to test whether epithelial 
permeability is indeed affected. 
Another possible explanation for how N. brasiliensis L3 antigen modifies the expression of 
cell-surface receptors and restriction factors involves the action of acetylcholinesterases 
present in the antigen preparation. Certain nematodes, including N. brasiliensis, secrete 
acetylcholinesterases, which function to suppress the host immune response and promote 
parasite survival (195-197). Interestingly this enzyme has been shown to increase the 
expression of the Muscarinic Acetylcholine Receptor M3 (M3 receptor) on rodent intestinal 
epithelial cells (198). Consequently, perhaps the acetylcholinesterase present in N. 
brasiliensis derived antigen is also able to alter other cell-surface receptors including cell-
surface vimentin. 
In conclusion, this study suggests that hookworm antigen may limit cervical cancer 
progression by inhibiting cell migration and reducing the proportion of cancer cells progressing 
to metastasis. 
4.2 The Influence of H. polygyrus Derived Antigens on Colorectal Cancer in vitro 
Despite several studies revealing a favourable role for H. polygyrus in the treatment of murine 
colitis, more recently Pastille et al., reported that infection with H. polygyrus exacerbates colitis 
associated colorectal cancer (CAC) tumour development and intestinal inflammation (103, 
124-127). This study therefore sought to determine the effect of antigen derived from this 
gastrointestinal nematode on CRC behaviour in vitro. 
The results from growth curve, MTT and BrdU Incorporation assays demonstrated that HES 
and H. polygyrus antigen significantly reduced the in vitro proliferation of both mouse 
(CT26.WT) and human (HCT116) colorectal cancer cells. Western blot analyses showed that 
this was associated with an upregulation of p53 and p21 expression. p53 and p21 are critical 
cell cycle regulator proteins, which act as tumour suppressors by preventing the progression 
from G1 into the S phase of the cell cycle (151). Importantly, other helminths have also been 
implicated in altering cell cycle progression. The nematode B. malayi suppressed the 
proliferation of several human carcinoma cell lines by inducing a G1 and G2 phase arrest, and 
T. spiralis derived antigen inhibited the proliferation of human myeloid leukemia and hepatoma 
cells by causing a halt in G1 and S (146, 199). In contrast to these encouraging results, O. 
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viverrini ES product increased in vitro proliferation of fibroblasts by causing elevated 
expression of proteins vital for the progression from G1 to S phase, phosphorylated 
retinoblastoma (pRB) and cyclin D1 (147). To definitively conclude whether HES and H. 
polygyrus antigen induce a cell cycle arrest, Propidium Iodide could be used to stain the DNA 
of fixed cells. Propidium Iodide is a dye which proportionately binds to DNA allowing the 
proportion of cells present in each phase of the cell cycle to be analysed by flow cytometry. 
Cells in G2, which have been through S phase and replicated their DNA would, therefore stain 
twice as bright as those in G1, which have not been through S phase or replicated their DNA 
yet, and cells in S phase would increase in brightness until complete DNA replication has 
occurred. 
Surprisingly, HES and H. polygyrus antigen had opposite effects on the migration of each 
colorectal cancer cell line, causing either a significant increase (CT26.WT) or decrease 
(HCT116) in cell migration. While unexpected, this differential effect on migration was 
supported by changes in β-catenin expression. β-catenin (NCBI Gene ID: 1499) forms part of 
the adherens junctions between cells and is negatively regulated by Adenomatous Polyposis 
Coli (APC) (200). Significantly, 85% of CRC cancers are associated with mutations in the APC 
gene, resulting in a loss of its tumour suppressor functions (200, 201). As a result, β-catenin 
expression becomes upregulated and acts as an oncoprotein. This activation of the Wnt 
signaling pathway, of which APC and β-catenin are a part, has been implicated in initiating 
CRC development and is associated with a poor prognosis (100, 166, 200). It is thus 
anticipated that the elevated level of expression of β-catenin in treated CT26.WT cells 
coincides with a significant increase in cell migration while the opposite is true for HCT116 
cells.  
The opposing transwell migration results observed between CT26.WT and HCT116 cells 
treated with H. polygyrus derived antigens could be due to the fact that these cell lines 
originate from different species. HCT116 (ATCC CCL-247) is a human epithelial colorectal 
cancer cell line and CT26.WT (ATCC CRL-2368) is a mouse fibroblast colorectal cancer cell 
line. However, to elucidate whether H. polygyrus derived antigens do indeed impact colorectal 
cancer cell migration in a species-specific manner, additional human and mouse colorectal 
cancer cell lines could be utilised and the described experiments repeated. Unfortunately, the 
two-dimensional scratch motility assay was not suitable to measure the migration of CT26.WT 
and HCT116 cells. CT26.WT cells do not form a monolayer and, therefore do not reach 100% 
confluency, meaning that one would not be able to reliably measure cell migration into the 
scratch. In contrast, HCT116 cells form a tight monolayer, which when wounded tears rather 
than forming a neat scratch. However, a radius cell migration assay may prove more 
appropriate. This assay similarly measures two-dimensional cell migration while incorporating 
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a biocompatible hydrogel spot. Cells are seeded in the well of a Radius plate surrounding the 
hydrogel, and once the cells have adhered the gel is dissolved leaving a gap into which the 
cells can migrate. The degree of migration into this space can then be quantified.  
4.3 H. polygyrus Derived Antigens and in vivo Colorectal Cancer Tumour Growth 
Once it had been determined that antigens derived from H. polygyrus were able to affect in 
vitro colorectal cancer cell proliferation and migration, further in vivo experiments were 
performed.  
A syngeneic tumour model showed that the growth of tumours derived from HES treated 
CT26.WT cells was significantly accelerated compared to those derived from untreated and 
H. polygyrus antigen treated CT26.WT cells. This treatment group also had raised levels of 
CD4+ and CD8+ T cells in the dLN. HES is known to contain a structurally distinct TGF-β 
mimic, which can signal via the canonical TGF-β receptor pathway and be antagonised by 
TGF-β receptor inhibitors (16, 33). Furthermore, this mimic can expand the Foxp3+ regulatory 
T cell (Treg) population in mice and humans. Consequently, the significantly elevated levels 
of Foxp3+ T cells present in the dLN and tumour of mice bearing tumours derived from HES 
treated CT26.WT cells was anticipated and confirmed that the HES was functioning as 
expected. Tregs have been implicated in dampening anti-tumour immunity and as a result are 
abundant in the tumour microenvironment (170-172). It is therefore possible that the increased 
growth of tumours in the HES treated CT26.WT group occurred as a result of TGF-β-induced 
Treg accumulation in the dLN and the tumour microenvironment and the inhibition of an 
effective anti-tumour immune response. 
Interestingly, both HES and H. polygyrus antigen increased the total number of CD11b+ cells 
and neutrophils present in the tumour. These cell populations have both been associated with 
enhanced colorectal cancer tumour growth and metastasis in mice and human studies, 
suggesting that the H. polygyrus derived antigens may be increasing CT26.WT tumour growth 
by expanding the CD11b+ and neutrophil populations in the tumour (202-204). 
The exact mechanism behind how HES accelerated CT26.WT tumour growth was not 
determined, however it may involve the Phosphatidlyinositde 3-Kinase (PI3K) pathway. PI3K 
signaling is an essential regulator of the cell cycle and is important in cell proliferation, survival 
and differentiation (205). Furthermore, the PI3K pathway has been implicated in the 
progression of several cancer types with inhibitors of this pathway already being FDA 
approved for their treatment (206, 207). Inhibiting the PI3K pathway causes an enhanced anti-
tumour immune response by depleting Tregs and increasing the amount of CD8+ T cells 
present in tumours (208-210). Significantly, PI3K inhibitors have been described in controlling 
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CT26.WT tumour growth by reducing the amount of Tregs present in the tumour (208). This 
result was however, reversed following the reintroduction of Tregs. Notably, other helminths 
as well as their derived antigens have been shown to impact the PI3K pathway. C. sinensis 
ES products activated the PI3K pathway, which increased the migration and invasion of 
CCA and hepatoma cells and elevated the expression of N-cadherin, vimentin and β-catenin 
and reduced the expression of ZO-1 (178). Similarly, O. viverrini exacerbated chemically-
induced CCA by inducing PI3K signaling (211). If the PI3K pathway is indeed activated by 
HES then incorporating an inhibitor of this pathway into the present study may result in 
reduced CT26.WT tumour growth. 
Another possible mechanism behind how HES accelerated CT26.WT tumour growth involves 
the action of Programmed Cell Death-1 (PD-1), a checkpoint inhibitor protein which plays an 
active role in immune tolerance (212). Unsurprisingly, both PD-1 and its ligand PD-L1 have 
been implicated in cancer progression. Certain helminths target host PD-L1 to upregulate its 
expression and suppress the immune response, thus facilitating their long-term survival in the 
host (213, 214). It is therefore possible that HES activates PD-L1, to enhance survival of H. 
polygyrus, and in doing so suppresses the host immune system leading to accelerated 
CT26.WT tumour growth. 
It is important to note that the accelerated growth of tumours derived from HES treated 
CT26.WT cells contradicts what was seen in vitro where the proliferation of these cells was 
significantly reduced following treatment with both HES and H. polygyrus antigen. While the 
exact cause of this is unknown, it may be because the in vitro environment lacks critical 
components found in vivo. These include the presence of an intact immune response, high 
endothelial venules (HEVs) and the tumour microenvironment (215-218). Bearing the above 
in mind, perhaps the in vivo data is more convincing and reliable.  
In 2009 Bothelo et al., showed that antigen derived from adult S. haematobium accelerated 
the proliferation of Chinese Hamster Ovary (CHO) tumours, however there is little else known 
about the effect of helminth derived antigen on in vivo tumour growth (138). Therefore, the 
results obtained from this in vivo study are critical in helping to understand the role that 
helminths may play in cancer progression.  
4.4 The Involvement of HES and TGF-β in Colitis-Associated Colorectal Cancer (CAC) 
Infection with H. polygyrus has been shown to both inhibit and promote the development of 
colitis in vivo (103, 124). However, the role of HES in the development of colitis and CAC has 
yet to be determined. The results obtained from the model of CAC used in this study suggest 
that HES exacerbates CAC development. 
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Mice treated with HES/AOM/DSS had increased morbidity compared to untreated and 
AOM/DSS only treated mice. This was associated with increased weight loss, shorter colons 
and higher pathology scores, which coincided with elevated CD11b+, eosinophil and 
neutrophil cell proportions and total cell numbers in the spleen. Importantly, helminth infections 
have been shown to alter the CD11b+ population in murine models of CAC. Infection with T. 
crassiceps prevented the up-regulation of markers associated with CAC-tumorigenesis in 
mice and reduced the numbers of circulating CD11b+ Ly6C (hi) CCR2+ cells (100). Recently, 
STAT6, a transcription factor critical for the induction of Th2 immune responses, has been 
shown to exacerbate CAC and tumour development through expansion of the circulating 
CD11b+ Ly6C (hi) CCR2+ and CD11b+ Ly6C (low) Ly6G+ cell populations (219). HES may 
therefore, be worsening CAC pathology by activating STAT6 expression and the Th2 response 
leading to the expansion of CD11b+ immune cell populations.  
While H. polygyrus derived antigens have not been reported to impact IBD or CAC, the effect 
that other helminth antigens have on these diseases has been explored. Antigen derived from 
T. spiralis and H. diminuta ameliorated DNBS-induced colitis by increasing immune-regulatory 
and decreasing pro-inflammatory cytokine expression and, similarly TcES inhibited CAC 
tumour formation by reducing pro-inflammatory cytokine and tumorigenesis marker 
expression (101, 114, 116, 220). Treatment with S. mansoni egg antigen (SEA) modulated 
disease symptoms in colitic mice through the preferential development of a Th2 response and 
by expanding the Foxp3+ T cell population, which successfully regulated the inflammatory 
response characteristic of colitis  (26, 221). 
Introducing a TGF-β inhibitor (SB-431542) into the study alleviated the symptoms associated 
with HES/AOM/DSS treatment. This would suggest that the TGF-β mimic present in HES is 
responsible for the increased morbidity and mortality in the HES/AOM/DSS treated mice. It is 
proposed that by inhibiting the TGF-β receptor and consequently TGF-β signaling, SB-431542 
results in reduced Treg population expansion and, therefore allows for the development of a 
more effective anti-tumour immune response which limits the morbidity associated with CAC 
(128, 129).  
Mice in the HES/AOM/DSS/SB-431542 treatment group also had CD11b+ cell proportions and 
numbers comparable to that of the untreated and AOM/DSS only treated groups. This further 
suggests that the TGF-β mimic present in HES is responsible for expanding the CD11b+ cell 
population. Interestingly, CD11b+ Gr-1+ cells have been reported to be responsible for the 
tumour-promoting effects of TGF-β in breast cancer (222, 223). Using the 4T1 breast cancer 
model, TGF-β neutralization resulted in reduced CD11b+ Gr-1+ cell numbers in the blood and 
dLN, which directly correlated with a reduction in tumour size. The results from this study, 
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therefore coincide with the present study, and it is hypothesised that the TGF-β-induced 
CD11b+ cell accumulation in the spleen of HES/AOM/DSS mice contributes towards the 
elevated CAC disease severity experience by this group. 
A caveat of the present study is the lack of a TGF-β inhibitor only group. TGF-β has a known 
role in EMT and cancer progression, therefore it cannot be ruled out that the alleviation of 
symptoms in the HES/AOM/DSS/SB-431542 group is due to the actions of the inhibitor only 
(224-227). Since only two mice from the HES/AOM/DSS treated group survived to the end of 
the experiment, no significant conclusions can be drawn from the colon length, spleen weight 
and spleen total cell count data. Furthermore, from day 12 onwards the HES/AOM/DSS/SB-
431542 treated mice started to experience worsened pathology, and this may have skewed 
the end results. This could be due to SB-431542 having a short half-life and perhaps the 
compound should have been administered once more towards the end of the experiment to 
further sustain its protective effect. It is important to repeat this study, including a SB-431542 
only group and possibly ending the experiment on day 12 to prevent mortality in the 
HES/AOM/DSS treated group and increased pathology in the HES/AOM/DSS/SB-431542 
treated group. 
It is important to note that the DSS used in each of the CAC studies, either with or without the 
SB-431542 inhibitor, were not from the same batch. The DSS used in the first study, without 
SB-431542, was found to be less efficient compared to previous and subsequent batches of 
DSS used. The mice in the first study, therefore experienced less inflammation and 
consequently were not as susceptible to the immune modulatory effects characteristic of HES. 
These mice ultimately had reduced morbidity and mortality, which was evident in the 
HES/AOM/DSS mice in the second study. 
These preliminary experiments suggest that exposure to gastrointestinal nematode derived 
antigen results in a poor outcome in CRC tumour growth and CAC development associated 
with an expansion of the Treg population. These results align with what is currently known 
about Tregs and CRC development and progression and implicate Tregs as a key driver of 
disease as well as a potential target in CRC treatment (128, 129). 
5. Conclusion 
The data presented here provides compelling evidence that helminth derived antigens can 
impact cancer development and progression. While hookworm exposure appears to have a 
protective impact on cervical cancer cell progression through inhibiting migration, EMT marker 
expression and HPV internalisation (Figure 4.1), exposure to gastrointestinal nematode 
antigens accelerated the development and progression of colorectal cancer by exacerbating 
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CAC symptoms and accelerating tumour growth (Figure 4.2). These findings highlight the 
complicated nature of cancer and the importance of understanding exactly how helminths can 
alter the behaviour of this disease. Further in-depth analysis could reveal a preventative and 
late-stage treatment for cancer using parasitic antigens. 
6. Future Work 
6.1 N. brasiliensis and Cervical Cancer 
It is critical to determine the mechanism behind how N. brasiliensis systemically alters EMT 
expression in the murine FGT. This could be achieved in several ways: 
Injecting N. brasiliensis infected mice with anti-IL-13 would neutralise the function of this 
cytokine and allow one to determine whether the expression of vimentin and N-cadherin is 
similarly decreased in the FGT of these mice compared to infected and naïve mice, which did 
not receive recombinant IL-13. Furthermore, IL-4 Receptor Alpha (IL-4Rα) deficient mice could 
also be utilised. IL-13 signals via IL-4Rα, therefore mice deficient in this receptor would not be 
responsive to IL-13 signaling. If N. brasiliensis infected IL-4Rα deficient mice have reduced 
expression of vimentin and N-cadherin in the FGT then one could conclude that IL-13 may be 
playing a role in systemically reducing EMT expression. 
Acetylcholine signals via the M3 receptor, therefore mice deficient in this receptor could be 
utilised to determine whether this neurotransmitter and the acetylcholinesterase produced by 
N. brasiliensis may play a role in altering EMT expression in the FGT. However, it is important 
to remember that acetylcholine has multiple receptors, therefore incorporating M3 receptor 
deficient mice into the study would only provide support for the role of acetylcholinesterase in 
systemically altering EMT expression and not conclusive evidence. Moreover, treating mice 
with acetylcholinesterase, instead of N. brasiliensis, could also be used to determine whether 
this enzyme has a similar effect on EMT expression in the FGT compared to live infection 
alone.  
Although the above described experiments would be beneficial in helping to determine the 
mechanism of action, which N. brasiliensis uses to impact cervical cancer development and 
progression it would be more useful to isolate an individual protein or lipid which directly 
mediates the observed effects on cervical cancer behaviour. This could be achieved using 





6.2 H. polygyrus and Colorectal Cancer  
A limitation of the syngeneic tumour model used in this study is that the CT26.WT colorectal 
cancer tumours were not grown in a physiologically relevant location. In future experiments, 
the cells could be administered intrarectally into the submucosa of mice (229). This is 
important because C26.WT cells grown in the colon, which contains a more appropriate 
microenvironment, may behave differently to the CT26.WT cells used in the syngeneic tumour 
model. 
PD-1 has been shown to play a critical role in the negative regulation of ILC-2s, an innate cell 
population expanded during helminth infection, by causing an increase in ILC-2 cell numbers 
and facilitating parasite expulsion (13, 230). It is possible that HES activates PD-1 to reduce 
ILC-2 population numbers and enhance H. polygyrus survival in the host. Consequently, the 
host immune response is suppressed leading to accelerated CT26.WT tumour growth. For 
this reason, it would be beneficial to determine the changes in the proportion of ILC-2s present 
in tumours derived from HES treated CT26.WT cells compared to tumours derived from 
untreated cells.  
Interestingly, HES has been reported to contain micro-vesicles encompassing microRNAs 
(miRNAs) (231). These exosomes can be internalized by mouse cells and play an essential 
role in host-parasite interactions and dampening the Th2 immune response. It would be 
fascinating to determine whether these exosomes are able to alter colorectal cancer cell 
behaviour in vitro and in vivo as well as the development of CAC in a way similar to that of the 
H. polygyrus derived antigens. To achieve this, the exosomes could be isolated from HES by 
ultracentrifugation and used in the described in vitro and in vivo studies. 
In addition to the above, it would also be beneficial to determine whether live infection with H. 
polygyrus has similar effects on CRC behaviour and CAC development as observed using 







Figure 4.1: Summary of results. N. brasiliensis L3 antigen decreased cervical cancer cell migration and 
EMT expression independent of the HPV status of the cell line. Furthermore, while the L3 antigens 
decreased cell-surface vimentin expression, HPV16 pseudovirion internalisation was reduced. The results 
from this study would suggest a reduced risk of cervical cancer development as well as the prevention of 
possible metastasis. Beneficial outcomes in disease progression are indicated with green arrows and 




Figure 4.2: Summary of results. H. polygyrus derived antigens decreased human and mouse colorectal cancer 
cell proliferation with an associated increase in cell cycle regulators. These antigens also modified colorectal 
cancer cell migration in a cell line dependent manner. Tumours derived from HES treated mouse colorectal 
cancer cells had accelerated growth with an accompanied expansion in Treg, neutrophil and CD11b+ cell 
populations. Furthermore, in a mouse model of Colitis-Associated Colorectal Cancer (CAC), HES treatment 
worsened pathology and increased morbidity and mortality. Beneficial outcomes in disease progression are 
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8.1 Heligmosomoides polygyrus antigen and HES Preparation 
Hanks Media: 
Supplemented with 100 µg/ml penicillin and 100 µg/ml streptomycin  
 
H. polygyrus Media: 
RPMI supplemented with 11.1 ml 25% glucose, 100µg/ml penicillin and 100µg/ml 
streptomycin, 100 µg/ml L-glutamine and 100 µg/ml Gentomycin 
 
MACs Buffer: 
1x PBS supplemented with 0.5%BSA and 2mM EDTA 
 
8.2 Cell Line Culture 
Dulbecco's Modified Eagle Medium: 
Supplemented with 10% foetal bovine serum (FBS – Gibco No. 10500064), 100 µg/ml 
penicillin (Sigma-Aldrich-Aldrich No. P032-10MU) and 100 µg/ml streptomycin (Sigma-
Aldrich-Aldrich No. S9137-25G) 
 
Roswell Park Memorial Institute Medium-1640: 
Supplemented with 10% foetal bovine serum (FBS), 100 µg/ml penicillin and 100 µg/ml 
streptomycin 
 
McCoy’s Modified 5a Medium: 
Supplemented with 10% foetal bovine serum (FBS), 100 µg/ml penicillin and 100 µg/ml 
streptomycin  
 
8.3 Mycoplasma Testing 
Fixative: 
3:1 Methanol: Acetic Acid 
 
Mounting Fluid: 
20mM Citric acid 
55mM Na2HPO4.2H2O 
50% Glycerol 










0.5g -20°C Trypsin (Sigma-Aldrich No. 79794) 
0.2g EDTA 
Make up to 1L with dH2O, pH 7.4 
Filter-sterilise through 0.2µm filter and autoclave 
 






Make up to 1L with dH2O, pH 6.9 and autoclave 
For use dilute to 1 X (100ml 10X PBS; make up to 1L with dH20) 
PBS/0.1% Tween: 
1ml Tween20 to 1X PBS 
 
Carnoy’s Fixative 
MeOH: Acetic Acid 3:1 
 
2M HCL 
60ml dH2O  
40ml 10 N HCL 
 
PBS/0.5% Tween20 
200ml of 1X PBS 
100µl Tween20 
Mix and store at 4°C 
 
0.1M Borate Buffer 
7.6g Sodium Borate (borax MW=381.4) 
200ml of dH2O 
116 
 
Mix and pH to 8.5 with HCL 
 
Lidocaine-EDTA: 
4mg/ml Lidocaine (Sigma-Aldrich L5647-15G) and 10mM EDTA  
 
8.5 Western Blotting 
SDS-PAGE Buffer/Boiling Blue: 10ml 
832µl 1.5M Tris-HCl (pH 6.8) 




Pinch of bromophenol blue 
70µl of boiling blue was added to a 100% confluent well of a 6cm dish 
 
Sodium Dodecyl Sulphate (SDS)-polyacrylamide gels 
Acryl-bisacryl-amide mix (30:08): 
29 g acrylamide 
1g N,N’‐methylenebisacrylamide 
Make up to 100ml, heat at 37°C to dissolve chemicals. 
Store at 4°C, protected from light 
10% Sodium dodecyl sulphate (SDS): 
100g SDS 
Make up to 1L with dH20, pH 7.2 
Store at room temperature 
 
10% Ammonium persulphate (APS): 
0.1g Ammonium persulphate (Promega No. V3131) 
Make solution up to 1ml with dH20 
Store at 4°C 
 
4% Stacking gel (1): 
3.635ml dH20 
625µl 40% Acrylamide  
630µl 1.5M Tris (pH 6.8) 




50µl 10% Ammonium persulphate 
 
6% Resolving gel: 
5.5ml dH20 
1.5ml 40% Acrylamide  
2.5ml 1.5M Tris (pH 8.8) 
100µl 10% SDS 
10µl TEMED 
100µl 10% Ammonium persulphate 
 
8% Resolving gel: 
5.03ml dH20 
2ml 40% Acrylamide  
2.5ml 1.5M Tris (pH 8.8) 
100µl 10% SDS 
10µl TEMED 
100µl 10% Ammonium persulphate 
 
15% Resolving gel: 
3.5ml dH20 
3.75ml 40% Acrylamide  
2.5ml 1.5M Tris (pH 8.8) 
100µl 10% SDS 
10µl TEMED 
100µl 10% Ammonium persulphate 
 




pH 8.3 and make solution up to 1L with dH20 
For use dilute to 1 X (100ml 10X PBS; make up to 1L with dH20) 
 
10X Transfer buffer: 
38g Tris 
144g Glycine 
Make solution up to 1L with dH20 and store at 4°C 
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For use dilute 1 X (100ml 10 X Transfer Buffer, 200ml Methanol and 700ml dH20) 
Store at 4°C 
 
Tris buffered saline (TBS)/0.1% Tween20 
10X TBS: 
6.05g 50mM Tris 
8.76g150mM NaCl  
Make up to 1L, pH 7.5 and autoclave 
For use dilute to 1 X (100ml 10X TBS; make up to 1L with dH20) 
TBS/0.1% Tween: 
1ml Tween20 to 1X TBS 
 


















8.6 In vivo Experiments 
FACs Buffer: 
1x PBS supplemented with 5%BSA and 1% Sodium Azide 
 
4% paraformaldehyde 
Dilute 37% formaldehyde to 4% using 1X PBS 
 
Thermo Scientific PageRulerTM Prestained Protein Marker.  
